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ABSTRACT 
Cutaneous melanoma is one of the most aggressive malignancies, typified by a high 
metastatic tendency and refractoriness to treatments. Identification of the molecular 
mechanisms behind the development and progression of melanomas is of utmost importance 
to gain new insights into treating this notorious disease. The aim of this study was to identify 
genes and proteins associated with melanoma development and progression by comparing the 
genome-wide gene expression profiles from different stages of melanoma, and to further 
characterize the most interesting genes functionally, as well as evaluate their potential as 
diagnostic and prognostic markers and therapeutic targets. A further aim was to develop 
sensitive RT-PCR and immunohistochemical assays for the detection of melanoma 
micrometastases. 
By comparing the gene expression profiles of melanoma lymph node micro- and 
macrometastases, we found the metastatic outgrowth to be commonly associated with 
increased TGFβ/Smad2 signaling in melanoma cells and associated fibroblasts as well as 
with an up-regulation of TGFβ-target genes encoding extracellular matrix (ECM) proteins 
fibronectin (FN1), collagen-I (COL-I), periostin (POSTN), and versican (VCAN). 
Interestingly, we found these proteins to form together intricate fibrillar networks around 
tumor cells especially at the tumor-stroma interface in melanoma and breast cancer 
metastases from various organs. Our in vitro functional assays suggested that these channel-
like structures provide a scaffold for the metastatic cells to adhere and that they promote the 
growth and migration of both tumor cells and stromal fibroblasts and endothelial cells. In 
addition, POSTN and cellular FN1 were found to be specifically up-regulated in angiogenic 
tumor blood vessels. Combined, these results suggest that TGFβ signaling and especially the 
TGFβ-target genes, POSTN and FN1, are attractive therapeutic targets for treating 
disseminated melanomas and breast cancers, as they affect many key processes of metastasis. 
In the analyses of benign nevi and primary melanomas, we found collagen triple helix repeat 
containing 1 (CTHRC1) to be commonly up-regulated in melanoma development and 
progression. In RT-PCR analyses of primary cells and cell lines as well as in 
immunohistochemical stainings of melanoma tissues, we found CTHRC1 to be expressed by 
tumor cells as well as by stromal fibroblasts and blood vessel endothelial cells. In our in vitro 
analyses, knockdown of CTHRC1 expression in melanoma cells inhibited their migration 
through transwell inserts as well as their migration and invasion in three-dimensional (3D) 
9 
 
matrices. Our analyses suggested that the expression of CTHRC1 is regulated coordinately 
with FN1 and integrin β3 (ITGB3) by the pro-invasive and pro-angiogenic transcription 
factor, the nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 
(NFATC2), providing thus an interesting target for therapy. Further, high mRNA expression 
of CTHRC1 and FN1 in primary melanomas was associated with short survival, suggesting 
that these genes also show potential to serve as prognostic factors. 
We also found a common up-regulation of cysteine cathepsin B and L1 (CTSB and CTSL1) 
proteases during melanoma progression. High CTSB mRNA expression in primary 
melanomas was also found to be a potential prognostic factor, correlating with poor survival. 
By immunohistochemical stainings, CTSB was found to be expressed by the melanoma cells 
especially at the invasion front, while CTSL1 was expressed by fibroblasts surrounding the 
melanoma cell nests. Interestingly, the staining intensity of CTSL1 was increased with the 
depth of melanoma cell invasion. We then tested the significance of these and other proteases 
in melanoma cell invasion in a co-culture system with fibroblasts in 3D Matrigel. In this 
assay, fibroblasts dramatically promoted the invasive growth of melanoma cells and appeared 
to lead the invasion of the cells. This co-invasive process was found to be dependent on 
TGFβ signaling and the activity of cathepsins B and L1 but not of matrix metalloproteinases 
(MMPs). These results further strengthen the importance of TGFβ in melanoma progression 
and suggest that inhibition of TGFβ signaling as well as blocking the activity of cathepsins B 
and L1 is a therapeutic strategy worthy of testing in the treatment of invasive melanomas. 
In another part of this work, we identified the best gene expression marker genes for the 
detection of melanoma metastases by comparing the gene expression profiles of normal and 
micrometastatic lymph nodes. Of the identified genes, MLANA, TYR, MIA, PRAME, and 
SPP1 were tested as potential melanoma micrometastasis markers by RT-PCR and 
immunohistochemistry (IHC). In the analysis of 160 patients, graded MLANA- and TYR-
RT-PCR analyses detected clinically significant metastases better than IHC, suggesting that 
quantifiable RT-PCR analyses should be used to confirm and complement histological and 
immunohistochemical examinations in the analyses of melanoma sentinel lymph nodes for 
metastatic disease. Further, the melanoma-specific genes, PRAME and SPP1, may be used to 
differentiate melanoma cells from benign nevus cells frequently residing in the sentinel 
lymph nodes. These genes may also serve as potential therapeutic targets for the treatment of 
metastatic melanomas. 
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ABBREVIATIONS 
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NFκB   nuclear factor κB 
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PDGF  platelet derived growth factor 
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INTRODUCTION 
The incidence of cutaneous melanoma, one of the most aggressive types of cancer, is rising 
rapidly all over the world. Over 1300 Finns are diagnosed with melanoma every year, making 
melanoma the sixth most common cancer in Finland (Finnish Cancer Registry). Cutaneous 
melanoma arises from pigment-producing melanocytes, which reside in the basal layer of the 
skin and protect the skin from UV radiation. Melanoma may spread to other parts of the body 
through lymphatic and blood vessels. The first site of metastasis is usually the regional lymph 
nodes (sentinel lymph nodes, SLNs) draining the primary melanoma site. The status of the 
SLNs serves as an early indicator of metastatic disease and is an important prognostic factor 
for survival (van Akkooi et al., 2010). Melanoma is usually curable by surgery in its early 
stages, but even though there are recent advances in the development of molecularly targeted 
therapies against disseminated disease (Flaherty et al., 2012), once the disease has spread to 
lymph nodes and clinically detectable metastases have been formed, melanoma is extremely 
difficult to cure and the median survival time of patients is less than a year. It would be very 
important to find the early occult metastases when immunotherapies and other treatments 
may still be effective. Also, accurate analysis of the SLN status may spare patients without 
disseminated disease from unnecessary morbidity caused by aggressive treatments. However, 
lack of specific markers prevents the use of sensitive molecular methods in the analysis of 
lymph nodes. The discovery of new specific diagnostic and prognostic markers as well as 
new therapeutic targets for metastatic disease is necessary to improve the survival of patients 
with this challenging disease. Unraveling the molecular mechanisms behind the different 
steps of metastasis: melanoma cell invasion and dissemination, formation of micrometastases, 
and the outgrowth of the metastases, is of utmost importance in this regard. Also, discovery 
of new potential molecular markers revealing metastatic traits present already in the primary 
melanomas could aid in predicting the progression of the disease. During the past few years, 
researchers have also focused more and more on studying the tumor microenvironment 
acknowledging that also the stromal cells play a significant role in the development and 
progression of many cancers, including melanoma. Identification of gene expression changes 
both in melanoma and stromal cells may aid in detection and prognostication of melanoma 
dissemination and reveal new targets for therapy.   
 
                                                                                                                             Review of the Literature 
13 
 
REVIEW OF THE LITERATURE 
1. MELANOMA 
1.1 Melanoma development 
Cutaneous melanoma arises from pigment-producing melanocytes, which reside in the basal 
layer of the skin and protect the skin from UV radiation (Figure 1). Severe sun burns early in 
life and intermittent pattern of intense sunlight exposure among fair-skinned individuals are 
thought to be the main risk factors for melanoma (Thompson et al., 2005). UV radiation can 
promote the malignant transformation of the melanocytes by directly causing mutations in the 
DNA, by reducing immune defenses in the skin, and by creating DNA damaging reactive 
oxygen species (Thompson et al., 2005). The development of melanoma from melanocytes is 
thought to be a stepwise process (Villanueva and Herlyn, 2009).  In normal skin, the 
phenotype and growth of normal melanocytes is strictly controlled by the surrounding 
keratinocytes. When this control is lost, melanocytes may divide and form a non-malignant 
melanocytic growth, a benign nevus. The nevus cells may acquire genetic changes and form a 
dysplastic nevus, which may develop further into a radial growth phase (RGP) malignant 
melanoma. RGP melanomas usually grow horizontally and rarely metastasize. 
Approximately 90% of melanomas in this stage can be cured by surgical excision. The RGP 
melanoma may acquire additional genetic and epigenetic changes and progress to the vertical 
growth phase (VGP), which is associated with increased risk of metastasis. In this stage, the 
melanoma cells have the ability to invade into dermis and subcutaneous tissues. Melanoma 
metastasizes to lymph nodes and other organs via lymphatic or blood vessels. 
Although the linear progression model of melanoma has been widely acknowledged, a high 
proportion of melanomas are diagnosed without any association with previous benign or 
dysplastic nevi, indicating that melanoma may also develop directly from single melanocytes 
or melanocyte precursor cells (Figure 1) (Zabierowski and Herlyn, 2008). Whether the 
melanoma-initiating cells are true cancer stem cells, and whether melanoma propagates 
through a cancer stem cell model, in which a small population of highly tumorigenic self-
renewable cells drive the tumor growth and generate irreversibly less or non-tumorigenic 
differentiated cells forming the bulk of the tumor, is under a lot of research and debate 
(Shackleton and Quintana, 2010). Understanding the nature of melanoma progression is 
highly important to be able to develop rational treatment strategies. 
Review of the Literature 
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1.2 Classification 
Cutaneous melanoma is a very heterogeneous disease. Classically primary melanomas have 
been categorized into subtypes based on clinical and histopathological criteria (McGovern et 
al., 1973). However, the validity of this classification system has been debated, because it 
holds no prognostic value, does not predict any differences in treatment responses (Romano 
et al., 2011), and some of the histological criteria overlap between subgroups (Busam, 2010). 
A new emerging molecular classification system, in which recently discovered molecular 
signatures and mutations are incorporated into the classical histopathological classification 
system, may aid in developing new targeted therapies and selecting effective treatments for 
patients (Romano et al., 2011).     
1.2.1 Histopathological classification 
The four main clinico-histopathological subtypes of cutaneous melanoma are superficial 
spreading melanoma (SSM, ≤70%), nodular malignant melanoma (NMM, ≤20%), lentigo 
malignant melanoma (LMM, ≤10%), and acral lentiginous melanoma (ALM, rare) 
Figure 1. Classical stages of melanoma progression. 
Advanced melanomas may develop either through a 
stepwise progression or in some cases directly from 
transformed melanocytes. Malignant transformation is 
dependent on genetic and environmental factors, such as 
UV radiation. Tumor progression is further promoted by 
increased heterotypic signaling between melanoma cells 
and untransformed stromal cells and by alterations in the 
tumor microenvironment. Modified from Villanueva and 
Herlyn, 2009. 
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distinguished by histopathology, anatomical site, and degree of sun damage (Kamarashev et 
al., 2011). SSM and LMM are differentiated by their intraepidermal growth pattern in the 
early phase (RGP) of the development and ALM by its anatomical location (palms, soles, nail 
beds) in addition to its RGP growth pattern (Whiteman et al., 2011). NMMs, in contrast, are 
preferentially located on the trunk and are characterized by the lack of significant RGP 
(growing vertically from the beginning of the development) (Kamarashev et al., 2011). SSMs 
are preferentially located on areas that are intermittently and LMMs on areas that are 
chronically exposed to UV radiation. 
1.2.2 Molecular classification 
1.2.2.1 Genomic aberrations 
Two major molecular signaling pathways affected in melanoma development are the 
mitogen-activated protein kinase (MAPK) and the phosphatidylinositol 3-kinase (PI3K)-AKT 
pathways, which regulate genes involved in cell proliferation and survival (Figure 2). BRAF, 
a serine threonine kinase of the MAPK pathway, is the most frequently mutated gene in 
melanoma, harboring mutations in approximately 50% of primary melanomas (more common 
in melanomas arising in intermittently sun-exposed skin) and in over 80% of benign nevi, 
suggesting that BRAF mutations are acquired early in melanoma development (Tsao et al., 
2012). Nearly 90% of BRAF mutations result in a kinase activating V600E substitution 
(Flaherty et al., 2012). 
Figure 2. MAPK and PI3K-AKT 
signaling pathways in melanoma. 
Activation of receptor tyrosine kinases 
through ligand binding leads to the 
translocation of NRAS to the cell 
membrane and subsequent activation of 
MAPK and PI3K-AKT pathways, which 
affect many cellular processes including 
cell proliferation, apoptosis, adhesion, 
migration, and differentiation 
(Bogenrieder and Herlyn, 2011). Genes 
found to have frequent activating 
mutations and/or amplifications in 
melanoma are marked with asterisks. 
The tumor suppressor PTEN inhibiting 
the PI3K-AKT pathway is inactivated 
by point mutations and deletions. 
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In primary melanomas, similar mutation frequencies to BRAF were recently found in the 
promotor region of the telomerase reverse transcriptase (TERT) gene (Heidenreich et al., 
2014; Horn et al., 2013; Huang et al., 2013). These activating mutations increase TERT 
expression by generating new binding sites for Ets transcription factors (Horn et al., 2013), 
many of which are downstream targets of the MAPK pathway. Interestingly, the mutations in 
the TERT promoter were found to be more frequent in BRAF mutant primary melanomas, 
suggesting a potential link between increased MAPK signaling and telomerase activity in 
melanoma development (Heidenreich et al., 2014; Horn et al., 2013). 
Another gene mutated frequently in melanomas is NRAS, encoding a small G protein 
activating both MAPK and PI3K-AKT pathways. NRAS is activated by point mutation in 
~20% of primary melanomas, mostly mutually exclusive to BRAF mutations (Flaherty et al., 
2012). Melanomas with wild-type BRAF and NRAS harbor frequent amplifications in cyclin-
dependent kinase 4 (CDK4) and cyclin D1 (CCND1) genes, which are positive regulators of 
the cell cycle and downstream targets of the MAPK pathway (Figure 2) (Bogenrieder and 
Herlyn, 2011).  
The PI3K-AKT pathway can also be activated in a subset of melanomas by 
amplification/overexpression of AKT3 (25%) or inactivation of the tumor suppressor 
phosphatase and tensin homolog (PTEN), encoding a phosphatase counteracting the PI3K, by 
point mutation or deletion (Bogenrieder and Herlyn, 2011; Flaherty et al., 2012) (Figure 2). 
PTEN is lost in 50-60% of melanomas, some of which also harbor a BRAF mutation 
activating the MAPK pathway, highlighting again the importance of the activation of both of 
these pathways in melanoma development (Flaherty et al., 2012). The two pathways are also 
activated by point mutations and/or amplifications of the receptor tyrosine kinase-encoding 
genes ERBB4 in 15-20% of all types of melanoma or KIT in 20-25% of mucosal, acral, or 
chronically sun-damaged melanomas (1% overall, wild-type for NRAS and BRAF). Many 
clinical trials targeting the components of MAPK and PI3K pathways are currently ongoing 
or in development. BRAF and KIT inhibitors have produced promising but mainly 
incomplete or unstable clinical responses (Flaherty et al., 2012). Likely, there are still 
unidentified contributing oncogenes influencing the outcomes of these treatments. 
Another important pathway affected in melanoma development, especially in familial 
melanomas, is the retinoblastoma (RB) pathway regulating the G1/S checkpoint in the cell 
cycle (Tsao et al., 2012). The CDKN2A locus encoding the tumor suppressor protein 
                                                                                                                             Review of the Literature 
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p16INK4A, which negatively regulates the cell cycle by inhibiting CDK4/6, is lost, mutated, or 
methylated in 25% of primary tumors (Bogenrieder and Herlyn, 2011). The CDKN2A locus 
also encodes, by using alternative splicing and a different reading frame, another tumor 
suppressor protein p14ARF, which inhibits p53 destruction by binding HDM2. Thus, CDKN2A 
inactivation eliminates both the RB and p53 pathways. Importantly, absence of nuclear p16 
expression in VGP melanomas has been found to associate with poor prognosis (Straume et 
al., 2000). 
 
1.2.2.2 Gene expression signatures 
Another way to classify tumors molecularly is by analyzing the genome-wide mRNA levels. 
Kauffman et al. (Kauffmann et al., 2008) compared the gene expression patterns of primary 
melanomas with and without metastasis (follow-up 4 years) and found that the most 
significant biological pathways associated with metastasis were the DNA replication and 
DNA repair pathways, suggesting that genetic stability is necessary for metastatic 
progression. Bittner et al. (Bittner et al., 2000), in turn, found primary melanomas to cluster 
into two groups and the presumably less aggressive group to show reduced expression of 
genes associated with cell spreading or migration, such as WNT5A, integrin β1, integrin β3, 
syndecan 4, vinculin, and fibronectin. 
The analysis of whole-genome gene expression profiles has also been used to classify 
melanoma metastases. By using unsupervised hierarchical clustering, Jönsson et al. (Jönsson 
et al., 2010) identified four distinct subtypes of distant metastases, characterized by 
expression of genes associated with immune response, pigmentation/melanocyte 
differentiation, proliferation, or presence of stromal components. Interestingly, metastases in 
the proliferative subgroup harbored more frequently BRAF and NRAS mutations and no 
double wild-type genotypes. Also, a higher frequency of CDKN2A homozygous deletions 
was found in the proliferative subgroup. Most importantly, they found a significant difference 
in the clinical outcome between the subtypes, with patients suffering from tumors of the 
proliferative subtype showing the shortest survival. In addition, in an independent cohort of 
metastatic melanomas, low expression of immune response-related genes was found to be 
significantly associated with poor prognosis. 
The analysis of genome-wide mRNA levels has also been used to reveal gene expression 
changes associated with different transition points in melanoma progression. Haqq et al. 
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(Haqq et al., 2005) found that the transition from the RGP to VGP in a large primary 
melanoma was associated with down-regulation of a set of genes including cell adhesion and 
extracellular molecules, such as P-cadherin (CDH3), MMP10, integrin α2, and laminin γ2. 
Interestingly, most of the genes in this gene set were found to be over-expressed in one 
subtype of melanoma metastases identified in their study, suggesting that some metastases 
may arise from RGP melanomas, which are mainly thought to lack the capability to 
metastasize. Riker et al. (Riker et al., 2008) in turn, searched for genes associated with 
melanoma progression and metastasis by comparing the gene expression profiles of thin non-
metastatic primary melanomas and melanoma metastases. The metastases were found to 
express for example higher levels of genes encoding tumor antigens (MAGE and CSAG2) as 
well as genes associated with melanoma progression (GDF15, MMP14, and SPP1), cell cycle 
progression (CDK2, TYMS, and BUB1), and inhibition of apoptosis (BIRC5 and BCL2A1). 
Also, they found the expression levels of many of these genes to change into more metastatic-
like as the thickness of the primary melanoma tumor increased. Most interestingly, the 
change in expression occurred at different thicknesses for different genes, suggesting that the 
tumor acquires more metastatic traits as it gets thicker. Similar findings have been reported in 
another study, where the metastasis gene signature was found to overlap the gene signature 
for increased tumor thickness (Jaeger et al., 2007). Also Smith et al. (Smith et al., 2005) 
found two distinct molecular profiles which differentiated the VGP primary melanomas and 
melanoma metastases from the RGP primary melanomas and benign nevi, suggesting that the 
major gene expression changes occur during the transition from RGP to VGP. 
Many have also tried to identify the molecular differences between cultured normal 
melanocytes and melanoma cells by comparing their gene expression profiles (reviewed in 
Hoek, 2007). Melanoma antigens (MAGEA6, MAGEA3, MAGEA12, and PRAME), N-
cadherin, and SPP1 were among the most significantly and reproducibly up-regulated genes 
in melanoma cells, and dipeptidyl-peptidase as well as E- and P-cadherins among the down-
regulated ones (Hoek, 2007). 
1.3 Staging and prognosis 
The most widely used cancer staging system in the world is the TNM (tumor-node-
metastasis) system. The TNM classification categories and stage groupings in melanoma 
recommended by the American Joint Committee on Cancer (AJCC) (Balch et al., 2009) are 
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presented in Table 1. In stages I and II, patients have no evidence of metastatic disease, and 
the main prognostic factor for survival is the thickness of the primary tumor as defined by 
Alexander Breslow in 1970 (Breslow, 1970). The next most powerful predictors of survival 
for localized disease are the ulceration status and the mitotic rate of the primary tumor (Balch 
et al., 2009). The five-year survival rates for patients with localized disease (with primary 
melanomas >1mm) are 53-91% depending on the thickness and the ulceration status of the 
primary tumor (Balch et al., 2010). Another widely used independent prognostic factor, the 
Clark’s level of invasion (Clark et al., 1969), has been omitted from the current AJCC staging 
recommendations for thin melanomas, because it was not found to be as a strong prognostic 
indicator as the other factors currently in use (Balch et al., 2009). 
 
Table 1. Melanoma TNM classification and staging according to AJCC. Modified from Balch et al., 
2009. 
Stage T classification 
Primary melanoma thickness 
(mm) 
Primary melanoma ulceration 
status/mitoses 
Five-year 
survival rate* 
0 T in situ - - - 
IA T1a ≤1.0 Without ulceration and mitoses <1/mm2 97% 
IB T1b ≤1.0 With ulceration or mitoses ≥1/mm
2 94% 
T2a 1.01-2.00 Without ulceration 91% 
IIA T2b 1.01-2.00 With ulceration 82% T3a 2.01-4.00 Without ulceration 79% 
IIB T3b 2.01-4.00 With ulceration 68% T4a >4.00 Without ulceration 71% 
IIC T4b >4.00 With ulceration 53% 
 
Stage N classification 
No. of metastatic 
nodes Nodal metastatic burden 
Primary melanoma 
ulceration status 
Five-year 
survival rate* 
IIIA N1a 1 Micrometastasis Without ulceration 78% N2a 2-3 Micrometastasis Without ulceration 
IIIB 
N1a 1 Micrometastasis With ulceration 
59% 
N2a 2-3 Micrometastasis With ulceration 
N1b 1 Macrometastasis Without ulceration 
N2b 2-3 Macrometastasis Without ulceration 
N2c - In transit metastases/satellites Without ulceration 
IIIC 
N1b 1 Macrometastasis With ulceration 
40% N2b 2-3 Macrometastasis With ulceration N2c - In transit metastases/satellites With ulceration 
N3 ≥4  With or without ulceration 
 
Stage M classification Site of metastases 
Serum lactate 
dehydrogenase levels 
One-year 
survival rate* 
IV 
M1a Distant skin, subcutaneous, or nodal metastases Normal 62% 
M1b Lung metastases Normal 53% 
M1c All other visceral metastases Normal 33% Any distant metastasis Elevated 
*Observed rates; from Balch et al., 2010. 
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As melanoma metastases are usually found first in the regional lymph nodes (the sentinel 
lymph nodes, SLNs) draining the primary melanoma site, most patients with stage IB or II 
melanoma are recommended to undergo sentinel node staging (see below) to detect possible 
occult metastatic disease (Balch et al., 2010). However, there is also a significant proportion 
(6.7%) of patients with thin melanomas (0.51 to 1.0 mm), who show SLN positivity, 
suggesting that analysis of the SLNs in patients with thin melanomas should also be 
considered (Murali et al., 2012). 
The SLN status alone is a strong predictor of survival, five-year survival rates being 83-94% 
for SLN-negative and 56-75% for SLN-positive patients (van Akkooi et al., 2010). Patients in 
stage III are diagnosed with SLN micrometastases or regional clinical metastases, and their 
prognosis is further influenced by the number of the metastatic nodes, the metastatic burden 
in the nodes, and the ulceration status of the primary tumor (Balch et al., 2009). The five 
year-survival rates for stage III patients varies from 40% to 78% (Balch et al., 2010). 
Although the removal of the rest of the lymph nodes in the tumor area (completion lymph 
node dissection) is associated with increased morbidity and has not been proven to have an 
effect on overall survival, it is recommended to all SLN-positive patients as it helps to control 
regional disease progression (Wong et al., 2012). In stage IV, the patient has developed 
distant metastases, and the one-year survival rate is between 33% and 62%, with prognosis 
being worst for patients with visceral metastases (other than lung) and/or elevated serum 
lactate dehydrogenase levels (Balch et al., 2010). 
1.3.1. Analysis of sentinel lymph nodes 
In sentinel node staging, SLNs are mapped by injecting a radioactive substance and a marker 
dye intratumorally or next to the scar of the excised tumor, followed by SLN biopsy and 
immunohistopathological analysis of the lymph nodes. Lymph nodes are recommended to be 
bisected through the hilum, to detect melanoma cells most commonly located in the 
subcapsular sinus (Wen et al., 2011) (Figure 3). Many different sectioning and staining 
protocols have been developed to get reliable but cost-effective confirmation of the SLN 
status. Mostly, multiple sections with certain intervals are stained with hematoxylin & eosin 
and immunohistochemically (Wen et al., 2011). The most commonly used antibodies to 
detect metastatic melanoma cells recognize S100 calcium-binding protein B (S100B), melan-
A (MLANA/MART-1), or tyrosinase (TYR) (van Akkooi et al., 2010). Also the monoclonal 
antibody HMB45 (recognizing PMEL/SILV/gp100) is widely used. Antibodies to S100B 
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recognize melanoma cells with almost 100% sensitivity but are non-specific, staining some 
normal cell types of the lymph node as well as benign nevus cells sometimes residing in the 
lymph node capsule or trabeculae (Wen et al., 2011). Conversely, other above mentioned 
antibodies are quite melanocyte-lineage specific but their sensitivity is relatively low as up to 
25% of melanomas have lost the expression of these antigens (Wen et al., 2011). Also, none 
of these markers are able to differentiate between melanoma and benign nevus cells. 
 
 
Figure 3. Patterns of lymph flow 
through the lymph node. The 
interstitial fluid collected from tissues 
arrives into the lymph node via the 
afferent lymphatic vessels and is 
channeled to the subcapsular sinus 
(flow marked by arrows), where it is 
filtered by subcapsular macrophages 
for large particles, that are presented 
to B cells (Swartz and Lund, 2012). 
Lymph fluid then flows towards the 
hilum through trabecular sinuses and 
a scaffold formed by fibroblastic 
reticular cells (not shown) (von 
Andrian and Mempel, 2003).  
Melanoma cells are thought to enter 
the lymph node via the afferent 
vessels and get trapped in the 
subcapsular sinuses, where they may grow and replace most of the lymph node tissue and spread 
further to other parts of the body through the efferent lymphatic vessel or blood vessels (Dewar et al., 
2004). HEV=high endothelial venule. 
 
The observed SLN positivity among melanoma patients in different studies varies between 
10% and 30%, depending on the mean/median primary tumor thickness, proportion of 
ulcerated primary tumors, and the extent of sectioning and analysis of the lymph nodes (van 
Akkooi et al., 2010). In order to completely rule out the presence of occult metastatic disease, 
the whole lymph node should be sectioned and examined. This being impracticable, current 
analysis of only a part of the SLNs by histopathological methods leads to substantial false-
negative rates (9% to 21%) (van Akkooi et al., 2010). The use of more sensitive molecular 
methods, such as reverse transcription-PCR (RT-PCR), in the analysis of whole SLNs, could 
reduce the false-negative rates. However, the tissue architecture is destroyed when RNA is 
extracted for RT-PCR and the cells expressing the studied markers can no longer be 
identified, introducing the need for new more specific markers able to differentiate between 
melanoma and benign nevus cells. 
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2. TUMOR MICROENVIRONMENT 
A melanoma tumor mass consists not only of melanoma cells but also of non-malignant 
stromal cells, soluble components, and the extracellular matrix (ECM) (Figure 4). In normal 
tissues, the growth and behavior of cells is controlled by the surrounding cells and the ECM. 
In tumors, malignant cells can, however, escape this control and modify the behavior of the 
stromal cells and the composition of the ECM. Melanoma cells can recruit and activate 
fibroblasts, endothelial cells, and immune cells through soluble growth factors and cytokines 
(paracrine signaling) and through direct cell-cell contacts. The activated stromal cells, in turn, 
can promote the proliferation and invasion of the melanoma cells (tumor-stroma crosstalk, 
see Figure 5) and participate in tumor-promoting processes such as angiogenesis, 
lymphangiogenesis, and inflammation. Melanoma cells have also been found to express 
receptors for many growth factors secreted by themselves, suggesting that these growth 
factors function in an autocrine manner in addition to activating stromal cells. The tumor 
microenvironment has received enormous interest in cancer research during the past decade, 
and the extracellular molecules, tumor-associated stromal cells, as well as the heterotypic 
interactions between tumor and stromal cells are studied as potential targets for cancer 
therapy. 
 
Figure 4. Melanoma tumor microenvironment. The melanoma tumor mass contains, in addition to 
tumor cells, non-malignant stromal cells including fibroblasts, endothelial cells, and immune cells, 
which interact with the tumor cells via direct contacts and through soluble components, such as 
growth factors and cytokines, part of which are embedded in the extracellular matrix. 
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2.1 Stromal cells and epithelial keratinocytes 
2.1.1 Keratinocytes 
Keratinocytes reside in the epidermal layer of the skin in a ratio of ~35:1 to melanocytes 
(Figure 1) (Lee and Herlyn, 2007). In normal skin, keratinocytes are important in maintaining 
melanocyte homeostasis by controlling melanocyte proliferation via paracrine growth factors 
and cytokines, including interleukin (IL) 1β, tumor necrosis factor α (TNF-α), stem cell factor 
(SCF), epidermal growth factor (EGF), and endothelin 1 (Fukunaga-Kalabis et al., 2008), and 
through intercellular communication via cell-cell adhesion molecules, such as E-cadherin 
(see section 3.1.1.1.) (Villanueva and Herlyn, 2008). Transformation of melanocytes is 
frequently associated with a shift from E-cadherin to N-cadherin expression, which allows 
the escape from the control of keratinocytes. Switching of the cadherin class enables 
melanoma cells to contact N-cadherin-expressing fibroblasts and endothelial cells through 
homotypic interactions during migration and invasion into the tumor stroma and blood/lymph 
vessels (Villanueva and Herlyn, 2008). 
2.1.2 Fibroblasts 
Fibroblasts are the most abundant stromal cell type in tumors. Normally fibroblasts reside in 
the fibrillar ECM in connective tissues and take part in ECM production and in regulation of 
epithelial differentiation and inflammation (Kalluri and Zeisberg, 2006). All these processes 
are also needed in wound repair, in which fibroblasts play an important role (reviewed in 
Kalluri and Zeisberg, 2006). After wounding, fibroblasts are activated by many growth 
factors, such as transforming growth factor β (TGFβ), platelet derived growth factor (PDGF), 
Figure 5. Cross-talk between melanoma 
and stromal cells through growth factors, 
cytokines, and chemokines. Examples of 
autocrine and paracrine signaling between 
melanoma cells, fibroblasts, endothelial 
cells, and monocytes/macrophages are 
shown. Modified from Ruiter et al., 2002. 
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and fibroblast growth factor 2 (FGF2), also known as basic fibroblast growth factor (bFGF), 
secreted by the injured epithelial cells as well as the monocytes and macrophages that 
infiltrate the wound site. During wound healing, activated fibroblasts regulate the immune 
response by secreting cytokines and chemokines, such as IL-2 and monocyte chemotactic 
protein 1 (MCP1)/CCL2, and produce ECM components, which serve as a scaffold for the 
cells participating in the wound repair process. Activated fibroblasts also produce growth 
factors, including hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF1), EGF, 
and FGF2 that induce the proliferation of epithelial cells needed for skin regeneration. 
Similar activated fibroblasts, often called as cancer-associated fibroblasts (CAFs), are also 
found in the stroma of tumors. They are usually found to express α-smooth-muscle actin (α-
SMA) and are therefore also sometimes called as myofibroblasts. In normal tissues, after the 
wound is repaired, the fibroblast population returns to the resting state. In tumors, however, 
the activated state of the fibroblasts is sustained by growth factors produced constantly by the 
tumor cells and potentially by the fibroblasts themselves through autocrine growth factor 
loops. Tumors are therefore compared to wounds that never heal (Dvorak, 1986). 
In melanoma, melanoma cells are thought to recruit fibroblasts from local environment or 
from bone marrow (as circulating mesenchymal precursor/stem cells) and to induce their 
proliferation and activation by secreting TGFβ, PDGF, and FGF2 (Villanueva and Herlyn, 
2008). In addition to increased synthesis of ECM molecules, CAFs produce ECM-degrading 
proteases, such as MMPs and cathepsins (see section 3.1.3.), which increase the ECM 
turnover and alter the composition of the ECM. CAFs are also an important source of growth 
factors, such as IGF1, FGF2, TGFβ, HGF, and endothelin, which in turn promote the 
proliferation, survival, and invasion of the melanoma cells (Ruiter et al., 2002; Villanueva 
and Herlyn, 2008). This reciprocal activation (Figure 5) may be melanoma-stage dependent, 
as fibroblasts appear to have an inhibitory effect on RGP melanoma cells when co-cultured 
together but promote the growth of metastatic VGP melanoma cells (Cornil et al., 1991). It is 
not known, whether the switch in the effect is due to melanoma cells acquiring the capability 
of activating the fibroblasts or becoming refractory to inhibitory signals (Lee and Herlyn, 
2007). 
CAFs are also important regulators of inflammation. In a melanoma cell-fibroblast co-culture 
experiment, melanoma cells were found to induce a proinflammatory response in fibroblasts 
(Gallagher et al., 2005). Fibroblasts responded to co-culture by secreting cytokines and 
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chemokines, such as IL-1β, IL-8, CXCL1, CXCL2, and CCL2 (MCP1), of which IL-1β and 
IL-8 function also in other tumor-promoting processes, such as angiogenesis - the formation 
of new blood vessels. Other pro-angiogenic factors produced by CAFs are MMPs and 
paracrine growth factors, such as vascular endothelial growth factor (VEGF) and FGF2. 
CAFs are also able to interact with endothelial cells by differentiating into pericytes 
(Villanueva and Herlyn, 2008). 
2.1.3 Endothelial cells 
It is widely known that induction of angiogenesis, the formation of new blood vessels from 
pre-existing vessels, is necessary for growing tumors to ensure sufficient supply of nutrients 
and oxygen. The proliferation and migration of blood vessel endothelial cells is induced by 
tumor cells, CAFs, and inflammatory cells through soluble growth factors and cytokines, 
such as VEGF, IL-8, FGF2, PDGF, TGFβ, and placental growth factor (PGF) (Villanueva 
and Herlyn, 2008) (Figure 5). Tumor cells may also induce the growth of lymphatic vessels 
into the tumor by stimulating lymphatic endothelial cells with VEGF-C, FGF2, and PDGF 
(Cao, 2005). Tumor-associated blood vessel endothelial cells are found to reciprocally 
activate tumor cells by secreting FGF2 and IL-8, and to induce lymphangiogenesis by 
producing VEGF-C and PDGF (Cao, 2005; Villanueva and Herlyn, 2008). Angiogenesis and 
lymphangiogenesis are tightly controlled under normal physiological processes such as in 
wound healing, but in tumors, there is a major imbalance between anti- and pro-
angiogenic/lymphangiogenic factors resulting in abnormal and leaky vessels, which allow 
easier access for the tumor cells and provide important routes for tumor cell dissemination 
(Streit and Detmar, 2003). Melanoma cells have further been shown to express chemokine 
receptors CCR7 and CXCR4, which may facilitate their invasion into lymphatic and blood 
vessels expressing the corresponding ligands CCL21 and CXCL12, respectively (Murakami 
et al., 2004). 
2.1.4 Inflammatory and immune cells 
Eradication of abnormal cells by the immune system is an important anti-tumor mechanism. 
Tumor cells, however, can evade immune attacks by secreting immune-blocking factors and 
by promoting chronic inflammation, which suppresses the adaptive immune response 
(reviewed in Ilkovitch and Lopez, 2008). In addition, inflammation promotes angiogenesis as 
well as tumor cell proliferation, survival, and metastasis. Melanoma cells produce several 
cytokines and chemokines, such as colony stimulating factor 2 (CSF2), CCL2, IL-8, IL-1α, 
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and IL-6, which attract and activate immune suppressive dendritic cells, regulatory T cells, 
and myeloid-derived suppressor cells (MDSCs) (Ilkovitch and Lopez, 2008). TGFβ and IL-
10 secreted by these immune cells or melanoma cells suppress certain cells of the adaptive (T 
cells) and innate (natural killer cells) immune systems, and attract monocytes and induce their 
differentiation into tumor-associated macrophages (TAMs) in concert with melanoma-cell 
derived CCL2 and VEGF (Mantovani et al., 2008; Melnikova and Bar-Eli, 2009). TAMs, in 
turn, participate in many tumor-promoting processes, such as tissue remodeling, 
inflammation, angiogenesis, and lymphangiogenesis (Gomes et al., 2013). They also further 
increase the immune suppressive environment by producing TGFβ and IL-10, recruiting 
regulatory T cells, and promoting MDSC function (Ilkovitch and Lopez, 2008). Melanoma-
derived factors also recruit and activate neutrophils, which promote inflammation and tumor 
progression by secreting IL-8 and MMPs (Ilkovitch and Lopez, 2008). 
2.2 Extracellular matrix 
The ECM is a complex network of proteins, glycoproteins, proteoglycans, and 
polysaccharides, which comprises both the basement membrane, separating the epithelial 
cells from the stroma (produced together by epithelial and stromal cells), as well as the 
interstitial matrix (produced mainly by fibroblasts). The basement membrane consists 
primarily of collagen-IV (COL-IV), laminins, FN1, and linker proteins, and has a more dense 
structure than the interstitial matrix, where the most common components are fibrillar 
collagens, proteoglycans, and glycoproteins such as FN1 and tenascin C (TNC) (Lu et al., 
2012). These matrix proteins are frequently very large and complex, and contain several 
distinct conserved domains that can bind other ECM proteins, cell-surface receptors, and 
growth factors (reviewed in Hynes, 2009). The exact composition and structure of the ECM 
varies in different tissues and is under constant degradation, reproduction, and remodeling, 
the dynamics of which are often deregulated already in the early stage of cancer development 
mainly by CAFs (Lu et al., 2012). The ECM was long thought to mainly function in the 
maintenance of tissue morphology and homeostasis, but is now considered to affect almost all 
behavior of the cell (Figure 6). In cancer, abnormal ECM affects the behavior of both cancer 
and stromal cells, leading to increased angiogenesis and inflammation, which further promote 
invasion and metastasis of tumor cells (Lu et al., 2012). 
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Figure 6. ECM functions regulating cell behavior. Cell adhesion to the ECM by cell surface 
receptors, such as integrins, is essential in many processes such as cell proliferation and 
differentiation, cell polarization, and cell migration (1.). In addition, ECM may prevent or support cell 
migration by functioning as a migration barrier (2.) or track (3.) (Lu et al., 2012). For example, the 
migration of normal melanocytes from the epidermis to the dermis is prevented by the underlying 
basement membrane (Satyamoorthy et al., 2002), whereas linearized cross-linked collagen fibers 
allow rapid migration of cells (Lu et al., 2012). The biomechanical properties of the ECM can regulate 
the behavior of the cell, for example through focal adhesion complexes, consisting of integrins and 
various adaptor proteins, which link the ECM to the actomyosin cytoskeleton of the cell and activate 
signal transduction cascades resulting in gene expression changes (4.). Some ECM proteins and 
molecules (notably heparin and heparan sulfates of proteoglycans) can mediate signaling to the cells 
also by binding various growth factors, such as bone morphogenetic proteins (BMPs), IGF, HGF, 
FGFs, Hedgehogs, WNTs, TGFβ, and VEGF (Taipale and Keski-Oja, 1997). ECM may function not 
only as a signal reservoir (5.), which limits the accessibility of growth factors and creates growth 
factor gradients, but can also present signals (6.) or function as a low-affinity co-receptor (7.) (Lu et 
al., 2012). For example, 
binding of FGF to its 
receptor is mediated by 
simultaneous binding to 
heparin sulfate (Hynes, 
2009). Also, some 
intrinsic domains of ECM 
proteins, such as the EGF-
like domain of laminins or 
tenascins, may function 
directly as solid-phase 
ligands or, when cleaved, 
as soluble ligands to 
activate canonical growth 
factor receptors (Hynes, 
2009). Digestion of the 
ECM by proteinases, such 
as MMPs and cathepsins, 
may produce bioactive 
peptides (8.), regulating 
various processes. 
Modified from Lu et al., 
2012. 
 
2.2.1 Collagens 
Collagens (reviewed in Kadler et al., 2007), the most abundant protein components of the 
ECM and connective tissues, comprise a large family of triple helical proteins (at least 28 
members), which function in tissue assembly or maintenance, and play important roles in 
various processes such as tissue scaffolding, cell adhesion, cell migration, cancer, 
angiogenesis, tissue morphogenesis, and tissue repair. Collagens consist of three polypeptide 
alpha chains linked to each other by hydrogen bonds (Kadler et al., 2007), and are mainly 
produced by fibroblasts, myofibroblasts, osteoblasts, and chondrocytes (Bosman and 
Stamenkovic, 2003). The triple helical collagen (COL) domains contain repetitions of the 
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amino acid triplet Glycine-X-Y, where X is frequently a proline and Y a 4-hydroxyproline, 
and are flanked by non-triple helical (non-collagenous, NC) domains located in the amino- 
and carboxyl-termini of the alpha chain (Kadler et al., 2007). The NC domains are cleaved 
from fibrillar collagens (COL-I, -II, -III, -V, -XI, -XXIV, and -XXVII), exposing the binding 
sites for fibrillogenesis (Kadler et al., 2007). The most abundant fibrillar collagen, COL-I, is 
found to self-assemble into fibrils in vitro, but requires organizers, such as FN1 and FN1- and 
COL-binding integrins, to specify the location of fibril assembly, and nucleators, such as 
COL-V, to initiate fibrillogenesis in vivo (Kadler et al., 2008). The cleavage of the NC 
domains also reveals residues, which are involved in stabilizing covalent cross-links formed 
between adjacent fibrils (Kadler et al., 2007). In other collagens, such as the network-forming 
COL-IV (found primarily in basement membranes), the NC domains may mediate the 
formation of supramolecular networks or gain new functions when released by proteolysis 
(Egeblad et al., 2010). For example, the fragments tumstatin (cleaved from COL-IV), 
endostatin (from COL-XVIII), and restin (from COL-XV) may function as inhibitors of 
angiogenesis and tumor growth (Egeblad et al., 2010). 
The collagen family also includes fibril-associated collagens with interrupted triple helices 
(FACITs) (COL-IX, -XIII, -XIV, -XVI, -XIX, -XX, -XXI, and -XXII), which can be found 
covalently cross-linked to the fibrillar collagens. Collagens may also function as anchoring 
fibrils (COL-VII) or form beaded filaments (COL-VI, -XXVI, and -XXVIII). The 
transmembrane collagens (COL-XIII, -XVII, -XXIII, -XXV), in turn, contain short cytosolic 
amino-terminal domains and long extracellular triple helical domains, which may be shed by 
proteolysis (Kadler et al., 2007). To recognize the various triple helical collagens, cells use, 
in addition to integrins (integrins α1β1, α2β1, α10β1, and α11β1), several structurally and 
functionally differing receptors, including discoidin domain receptors (DDR1 and DDR2), 
glycoprotein VI, leukocyte-associated IG-like receptor 1, and mannose receptors (reviewed in 
Leitinger and Hohenester, 2007). 
An intense stromal reaction with increased production of fibrillar collagens, such as COL-I 
and COL-III, by fibroblasts is a frequent phenomenon in several types of tumors, and is 
found to associate with poor prognosis in some cancers (Egeblad et al., 2010; Villanueva and 
Herlyn, 2008). This kind of desmoplastic reaction is also suggested to play a role in the 
metastatic process, as gene expression signatures with increased expression of COL-I and its 
modifying enzymes, such as the cross-linking enzyme lysyl oxidase, are found to correlate 
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with elevated risk of metastasis (Egeblad et al., 2010; Kääriäinen et al., 2006). The tumor-
associated COL scaffolds differ markedly from normal COL fibrils in soft tissues, being more 
linear and stabile due to increased cross-linking of adjacent COL triple helices. These 
modified COL fibrils stiffen the ECM and induce changes in cell behavior, including cell 
proliferation, survival, and migration (Egeblad et al., 2010). Although the linearized COL 
fibrils function as migration tracks for tumor cells (Figure 6), they also form a physical 
barrier against cell invasion. Proteolysis of COL by proteinases, such as MMPs and 
cathepsins, is seen at the invasive front of many tumors, including melanoma (Labrousse et 
al., 2004) (see also 3.1.3). 
2.2.2 Fibronectin 
FN1 (reviewed in Hynes, 1985; Pankov and Yamada, 2002) is a large multi-domain ECM 
glycoprotein, which mediates important connections between the cell and the ECM, and 
regulates cell adhesion, migration, growth, and differentiation. In addition to being an 
abundant insoluble component of the ECM (the cellular FN, cFN) secreted by many cell 
types, high levels of a hepatocyte-secreted soluble form of FN (the plasma FN, pFN) is found 
in the plasma and other fluids of the body (Pankov and Yamada, 2002). Both types of FNs 
are secreted as disulfide-bonded dimers of ~250 kDa subunits, which are composed of three 
different types of modules: 12 type I repeats, 2 type II repeats, and 15 type III repeats. Two 
additional type III repeats, EDA and EDB domains, as well as a third region, V/IIICS, are 
subjected to alternative splicing, producing as many as 20 different FN1 isoforms in human. 
Plasma FN lacks both the EDA and EDB domains, but shows alternative splicing in the V 
region. Cellular FN, however, shows more variable cell-type-specific splicing, resulting in 
isoforms which differ in their cell-adhesive, integrin-binding, and solubility properties 
(Pankov and Yamada, 2002). EDA- and EDB-containing FNs are rare in normal adult tissues, 
but widely expressed in tumors as well as in tissue repair, fibrosis, and angiogenesis (White 
et al., 2008). The alternative-spliced domains have been shown to have distinct functional 
properties. EDA has been linked to many functions, mainly in vitro, including cell adhesion, 
dimer formation, wound healing, matrix assembly, and mitogenic signal transduction (White 
et al., 2008). It has also been shown to play a role in fibroblast differentiation into 
myofibroblast in vitro and in lung fibrosis in vivo. EBD, in turn, plays a potential role in FN1 
matrix assembly (White et al., 2008), and has been proposed to induce a conformational 
change in FN1 revealing a cryptic integrin-binding site (Van Obberghen-Schilling et al., 
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2011). V region has been shown to participate in FN1 secretion and in integrin binding 
(Singh et al., 2010).  
FN1 has several short integrin-recognition sequences, including the best-known RGD (Arg-
Gly-Asp) domain, as well as the LDV and REDV sequences.  FN1 serves as a ligand for a 
dozen of integrins, of which the integrin α5β1 is the classical FN1 receptor (Pankov and 
Yamada, 2002). FN1 also interacts via its heparin-binding domain with the members of 
another cell-surface receptor family, the syndecans, which act as co-receptors for integrins 
(Schwarzbauer and DeSimone, 2011). Importantly, FN1 has various structurally and 
functionally differing binding domains, which allow simultaneous binding to other FN1 
molecules, other ECM molecules (including collagen and fibrin), cell surface receptors, and 
extracellular enzymes (Schwarzbauer and DeSimone, 2011). 
In the ECM, FN1 is assembled into fibrils, which surround and connect adjacent cells. The 
assembly of FN1 fibrils is a cell-dependent process. Compact FN1 dimers bind via their RGD 
cell-binding domains to the α5β1 integrins (may be compensated by αvβ1 integrin) and 
induce receptor clustering and recruitment of intracellular linker and signaling proteins to the 
cytoplasmic domains of the integrins. This leads to actin organization and an increase in cell 
contractility, which stretches the FN dimers and exposes new binding sites participating in 
fibril formation (Singh et al., 2010). COL-I has been found to enhance FN1 fibril assembly, 
possibly by increasing tension in the ECM (Singh et al., 2010). However, in developing 
tissues, the FN1 matrix is assembled before the formation of COL fibrils, suggesting that FN1 
plays a more important role in COL fibrillogenesis than vice versa. Also, the deposition of 
other ECM proteins, such as fibrillin, fibulin, latent TGFβ binding protein, and TNC, into the 
matrix has been found to be FN1-dependent (Singh et al., 2010). 
2.2.3 Laminins 
Laminins, the major components of the basement membranes, are conserved multidomain 
trimeric glycoproteins that provide structural support in tissues and regulate cell adhesion, 
migration, differentiation, and survival (Domogatskaya et al., 2012). The laminin 
heterotrimers are cross-, T-, or rod-shaped and are assembled from one α-, one β-, and one γ-
chain, all comprising multiple globular and rod-like domains (Durbeej, 2010). The five 
different α-, four β-, and three γ-chains existing in mammals are found to assemble into at 
least 16 isoforms with different cell or tissue specificities and patterns of expression 
(Domogatskaya et al., 2012). The secreted laminin heterotrimers may be processed 
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proteolytically in the extracellular space before they are assembled into networks (Durbeej, 
2010). Some laminins are capable of self-assembling into a matrix, but may also require cell-
surface receptors to mediate the assembly (Miner, 2008). Laminins bind several other 
basement membrane proteins, including nidogen, perlecan, and fibulin, to create a highly 
cross-linked matrix, and may also bind some components of the interstitial matrix 
(Domogatskaya et al., 2012; Durbeej, 2010). Laminins interact with cells via binding to cell-
surface molecules, including integrins (e.g. α1β1, α2β1, α3β1, αvβ3, α6β1, α6β4, and α7β1), 
dystroglycan, syndecans, Lutheran glycoprotein (also known as basal cell adhesion 
molecule), COL-XVII, and sulfated glycolipids (Domogatskaya et al., 2012; Miner, 2008). 
Laminins play important roles not only in normal processes, such as embryonic development 
and organogenesis (Durbeej, 2010), but also in cancer, affecting cancer progression from 
tumor development to metastasis (reviewed in Jourquin et al., 2010). 
2.2.4 Tenascins 
Tenascins are a conserved family of large cell-adhesion-modulating ECM glycoproteins with 
four family members, TN-C, -R, -W, and -X, each showing a different spatial and temporal 
expression pattern (Chiquet-Ehrismann and Tucker, 2011). The most studied of the tenascins, 
TNC, is highly expressed in embryonic development, wound healing, inflammation, and 
tumorigenesis, and is found to regulate many cellular processes, including cell proliferation, 
migration, and differentiation (Chiquet-Ehrismann and Tucker, 2011). Tenascins are 
primarily produced by the cells of the connective tissues and they all share a similar modular 
structure of an amino-terminal oligomerization domain, followed by EGF-like repeats, FN 
type III repeats, and a carboxyl-terminal fibrinogen globe, and they are assembled into 
trimers (TNR), hexamers (TNC and TNW), or oligomers (TNX) (Chiquet-Ehrismann, 2004). 
TNC has nine additional FN type III repeats that undergo alternative splicing resulting in 
numerous different isoforms, with larger ones being often tumor-specific (Chiquet-
Ehrismann, 2004). Tenascins can regulate cell adhesion and migration either directly by 
binding several cell-surface receptors, including integrins (α2β1, αvβ3, α7β1, α8β1, α9β1, 
α5β3, and α5β6), EGF receptors, and MET, or by inhibiting cell adhesion to FN1 by binding 
to the syndecan 4 binding site of FN1 (Brellier and Chiquet-Ehrismann, 2012; Chiquet-
Ehrismann and Tucker, 2011). TNC is also able to bind other ECM components, such as 
heparin, perlecan, versican, and collagen, and it may increase ECM production by controlling 
growth factor signaling (Midwood and Orend, 2009). 
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2.2.5 Periostin 
Periostin (POSTN) (reviewed in Kudo, 2011; Morra and Moch, 2011), also called osteoblast 
specific factor 2 (OSF-2), is a secreted matricellular protein expressed widely in adult and 
embryonic tissues under normal and particularly stress conditions, such as mechanical stress 
and hypoxia. It is a 90-kDa protein with an amino-terminal signal peptide, followed by a 
cysteine-rich region (EMI domain), four fasciclin (FAS) domains, and a carboxyl-terminal 
hydrophilic domain subjected to alternative splicing (Morra and Moch, 2011). POSTN 
interacts with integrins (αvβ3, αvβ5, and α6β4) via its FAS domains and regulates various 
cellular processes, including cell adhesion, migration, and survival. POSTN has also been 
found to bind other ECM proteins and to regulate COL-I fibrillogenesis (Norris et al., 2007; 
Takayama et al., 2006). POSTN is expressed mainly by mesenchymal stromal cells and it 
plays important roles in several normal processes, such as bone and tooth formation and 
maintenance (reviewed in Merle and Garnero, 2012), cardiac development (reviewed in 
Norris et al., 2009), and wound healing (reviewed in Hamilton, 2008). POSTN is also 
expressed in a variety of tumor cell lines and tissues, including melanoma (Tilman et al., 
2007). 
2.2.6 Versican 
Versican (VCAN) (reviewed in Ricciardelli et al., 2009; Wight, 2002; Wu et al., 2005) is a 
large aggregating chondroitin sulfate proteoglycan, which forms, together with aggrecan, 
neurican, and brevican, the family of hyaluronan-binding proteoglycans, the hyalectins. It 
consists of a central glycosaminoglycan (GAG)-binding region flanked by two globular 
domains, the amino-terminal G1 domain with an immunoglobular-like motif and two 
hyaluronan-binding proteoglycan tandem repeats, and the carboxyl-terminal G3 domain with 
two EGF-like repeats, a carbohydrate recognition domain, and a complement binding protein-
like domain. Alternative splicing of the GAG-binding region results in at least four VCAN 
isoforms, V0 (~370 kDa), V1 (~263 kDa), V2 (~180 kDa), and V3 (~74 kDa), differing in 
length and in the number of attached GAG chains. VCAN is expressed mainly by stromal 
cells in the ECM of a variety of normal tissues and organs, and also in tumors, with 
differences in the expression patterns of different isoforms, as V0 is particularly expressed in 
the early embryonic development, and V0 and V1 in cancer (Ricciardelli et al., 2009). VCAN 
regulates many cellular processes, such as cell adhesion, survival, proliferation, migration, 
and angiogenesis by binding to cell-surface receptors CD44, via its GAG side chains, and to 
integrin β1 and EGFR, via its G3 domain (Wu et al., 2005). There are also some 
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contradictory results concerning VCAN functions in vitro and in vivo, which may be 
explained by the diversity in the VCAN structure and the composition of the ECM, as many 
of the functions of VCAN are mediated by binding to a variety of other ECM components, 
such as hyaluronan, COL-I, FN1, TNR, fibulin-1 and -2, and fibrillin-1 (reviewed in Wu et 
al., 2005). Some of the interactions between VCAN and other ECM molecules may also have 
an anti-adhesive effect on cells, as VCAN has been reported to inhibit melanoma cell 
adhesion to FN1 and COL-I (Touab et al., 2002).  
2.2.7 Collagen triple helix repeat containing 1 
CTHRC1 is a highly conserved glycosylated secreted protein expressed in various embryonic 
and adult tissues, typically at the epithelial-mesenchymal interface and sites with interstitial 
collagen expression (Durmus et al., 2006). The full-length CTHRC1 contains an amino-
terminal hydrophobic signal sequence and a short collagen domain of 12 Glycine-X-Y 
repeats, which is also found in the proteins of the C1q/TNF superfamily (Pyagay et al., 2005). 
CTHRC1 expression has been found to be increased in several types of cancers, including 
breast, colon, ovary, liver, and lung cancers, as well as in melanoma (Tang et al., 2006). 
CTHRC1 has been suggested to promote cell migration by regulating collagen synthesis and 
activating non-canonical Wnt signaling (Pyagay et al., 2005; Yamamoto et al., 2008). 
2.2.8 Osteopontin 
Osteopontin/secreted phosphoprotein 1 (SPP1) (reviewed in Anborgh et al., 2010; Wai and 
Kuo, 2008) is a matricellular glycophosphoprotein expressed by a variety of cells and tissues, 
including bone, vasculature, kidney, and inflammatory cells. SPP1 exists as three 
alternatively spliced isoforms, the full-length SPP1 and two shorter isoforms both missing 
one exon (reviewed in Gimba and Tilli, 2013). All isoforms undergo multiple cell-type-
specific post-translational modifications, such as serine/threonine phosphorylation, 
glycosylation, and tyrosine sulfation, producing proteins with molecular weights of 41-75 
kDa and potentially distinct functions. Secreted SPP1 has been shown to affect adhesion, 
migration, invasion, chemotaxis, and survival of cells by binding various integrins (αvβ1, 
αvβ3, αvβ5, α4β1, α5β1, α8β1, and α9β1) and CD44 receptors (isoforms v6-v10) (Wai and 
Kuo, 2008). SPP1 has also several cleavage sites for thrombin and MMPs (including MMP-3, 
-7, and -9) (Anborgh et al., 2010), and fragmentation of SPP1 is required for efficient binding 
of integrins (Wai and Kuo, 2008). SPP1 has also been found to regulate cell migration 
intracellularly by forming complexes with CD44 and ezrin in the leading edge of migrating 
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cells (Zohar et al., 2000). SPP1 plays important roles in many processes, such as immune 
regulation, vascular remodeling, wound repair, ECM proteolysis and remodeling, and cancer. 
In tumors, SPP1 can be expressed both by tumor and stromal cells, and elevated SPP1 levels 
have been associated with poor prognosis in many cancers (Wai and Kuo, 2008), including 
melanoma (Rangel et al., 2008). 
2.2.9 Growth factors tethered to the extracellular matrix – transforming growth factor 
β 
As mentioned previously, ECM molecules can bind various growth factors and affect their 
accessibility and activity (Figure 6). One of the most important growth factors associated 
with melanoma progression, also identified in our studies, is TGFβ. 
There are three different TGFβ isoforms (TGFβ1, TGFβ2, and TGFβ3) encoded by distinct 
genes. They are all produced as inactive precursor proteins, containing a pro-domain, the 
latency-associated peptide (LAP), which is cleaved from the mature protein by proteases. The 
mature TGFβ remains inactive by associating non-covalently to the LAP, forming a small 
latency complex (SLC). TGFβs are frequently secreted in large latent complexes (LLCs), in 
which the SLC is further bound by one of the latent TGFβ binding proteins (LTBPs). The 
LLCs are incorporated into the ECM through the LTBPs, which bind other ECM proteins, 
such as FN1 and fibrillins (whole process reviewed in Hynes, 2009). TGFβs can be released 
from the ECM by the degradation of the bound matrix proteins or the LAPs, after which the 
activated TGFβ can bind to its receptor, the type II serine/threonine kinase receptor 
(TGFβRII), on the cell surface. The constitutively active TGFβRII activates the type I 
receptor (TGFβRI) by phosphorylation, which in turn activates the receptor-associated 
downstream signal transducer SMADs (SMAD2 and SMAD3). The phosphorylated 
SMAD2/3 forms a complex with SMAD4 and translocates to the nucleus to regulate 
transcription of target genes together with other transcription factors (reviewed in Drabsch 
and ten Dijke, 2012). In addition to activating the canonical SMAD signaling, TGFβ has been 
found to activate other pathways, such as MAPK, PI3K/AKT, and nuclear factor κB (NFκB) 
signaling pathways (Drabsch and ten Dijke, 2012). 
TGFβs are pleiotropic growth factors playing important roles in many normal processes, 
including embryonic development and normal tissue homeostasis, as well as in cancer, where 
their role is complex (Drabsch and ten Dijke, 2012). In normal epithelial tissues and normal 
melanocytes, TGFβ acts as a tumor-suppressor by inhibiting cell proliferation and inducing 
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apoptosis, whereas in advanced tumors, TGFβ has pro-tumorigenic effects. Some epithelial 
tumor cells may acquire resistance to the TGFβ-mediated growth suppression quite early in 
their progression by mutation or deletion of the TGFβ receptors or SMADs, and later on by 
activation of oncogenes with potent pro-mitogenic effects that dominate the anti-mitogenic 
signals of TGFβ. In melanoma, mutations of the TGFβ receptors or SMADs are very rare, 
and in fact many melanoma cells express and secrete high quantities of all TGFβ isoforms 
and show constitutive autocrine activation of TGFβ receptors with fully functional SMAD 
signaling (Javelaud et al., 2008). The precise mechanism of resistance to TGFβ-mediated 
anti-proliferative effect in melanoma is still unclear, but may include constitutive activation 
of MEK/ERK signaling due to the frequent activating BRAF and NRAS mutations (see 
1.2.2.1) (reviewed in Perrot et al., 2013). The melanoma-secreted TGFβ promotes tumor 
progression both via autocrine and paracrine mechanisms. TGFβ has been shown to favor 
melanoma cell invasion and dissemination by inducing epithelial-to-mesenchymal-like 
transition (see 3.1.1.1) of melanoma cells during the switch from RGP to VGP through up-
regulation of MMP9 and integrins β1 and β3, and down-regulation of E-cadherin (Perrot et 
al., 2013). In the tumor microenvironment, TGFβ promotes angiogenesis and inflammation, 
suppresses immune surveillance (see 2.1.4), and activates fibroblasts to produce ECM 
molecules, including COLs, FN1, and tenascins, that support the survival and metastasis of 
melanoma cells (reviewed in Drabsch and ten Dijke, 2012; Perrot et al., 2013). 
 
3. TUMOR METASTASIS 
The formation of metastases is a complex process with multiple steps, including local 
invasion of tumor cells, intravasation into the blood or lymph vessels, survival in the 
circulation, arrest and extravasation into distant organs, survival in the distant location and 
formation of micrometastasis, and finally metastatic colonization (reviewed in Valastyan and 
Wenberg, 2011). Here, we will review only the first and the last steps of this cascade. 
3.1 Local invasion 
In order to spread to other parts of the body, tumor cells need to detach from the tumor mass 
and invade the surrounding tissue barriers, including the basement membrane and the 
interstitial matrix. Tumor cells use similar mechanisms for invasion as normal cells during 
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morphogenesis and in wound healing, requiring alterations in cell adhesion, migration, and 
proteolysis of ECM components. 
3.1.1. Cell adhesion 
Cell adhesion is essential for maintaining normal tissue architecture and homeostasis. In 
migration and invasion, cells need to detach from the existing surroundings and create new 
interactions with different types of cells and matrix molecules. 
3.1.1.1 Cell-cell interactions 
Cadherins are a family of homophilic calcium-dependent glycoproteins, which bind with their 
cytoplasmic tails to α-, β-, and γ-catenins to link to the actin-cytoskeleton, facilitate cell-cell 
adhesion, and regulate cell signaling (Haass et al., 2004). Type I classical cadherins include E 
(epithelial)-, P (placental)-, and N (neuronal)-cadherins, which are differentially expressed in 
different cell types. Normal melanocytes and keratinocytes express E-cadherin, while 
fibroblasts and endothelial cells express N-cadherin. During melanoma development, 
expression of E-cadherin is switched to N-cadherin, allowing malignant melanocytes to 
escape the control of keratinocytes and instead interact with stromal cells (Villanueva and 
Herlyn, 2008). One mechanism for this cadherin switch is the up-regulation of the TGFβ-
regulated Snail family of transcription factors. In addition to repressing E-cadherin and up-
regulating N-cadherin expression, Snail transcription factors down-regulate occludin and 
claudin expression, thus disrupting the tight junctions between melanoma cells and 
keratinocytes (Gaggioli and Sahai, 2007). Similar changes in expression and disintegration of 
adherens and tight junctions are seen in the epithelial-mesenchymal transition (EMT), where 
epithelial cells detach from epithelial sheets and gain mesenchymal properties, including 
increased invasiveness (Valastyan and Weinberg, 2011). In addition to the cadherin switch, 
melanoma cells express increased levels of several cell-cell adhesion receptors of the 
immunoglobulin superfamily of cell adhesion molecules (CAMs), such as MCAM, L1CAM, 
and VCAM, which facilitate interactions to other melanoma cells and stromal cells (reviewed 
in Haass et al., 2005).  
3.1.1.2 Cell-matrix interactions 
Integrins (reviewed in Giancotti and Ruoslahti, 1999; Hynes, 2002) are the most important 
cell-surface receptors mediating interactions between cells and the ECM. In addition, certain 
integrins are able to bind CAMs and function in direct cell-cell adhesion. Integrins are 
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heterodimeric glycoproteins, consisting of non-covalently linked α and β subunits, containing 
extracellular domains, single transmembrane domains, and short cytoplasmic tails. In 
mammals, there are 18 α and 8 β subunits, found to assemble into 24 dimers, which differ in 
their ligand specificity and signaling properties. Binding to the ECM promotes integrin 
clustering and the formation of focal adhesion complexes, where integrins associate with the 
actin cytoskeleton via adaptor proteins (e.g. talin, vinculin, and paxillin), and activate 
intracellular signaling pathways through various protein kinases [e.g. focal adhesion kinase 
(FAK), Src, and integrin-linked kinase (ILK)], that regulate many cellular processes, 
including proliferation, survival, migration, differentiation, and gene expression. The activity 
of many integrins can also be controlled from within the cell (termed inside-out signaling, in 
contrast to the outside-in signaling induced by extracellular ligand binding) through 
conformational changes, induced among others by chemokine or growth factor receptor 
signaling. Inside-out signaling is critical in processes where the cell needs to break existing 
contacts and create new interactions with the ECM, such as in cell migration (see 3.1.2). 
In cancer, altered expression and intracellular control of integrins enables tumor cells to 
modify their interactions with the environment and obtain a migratory and invasive 
phenotype (Kuphal et al., 2005). For example, normal melanocytes are found to express the 
laminin-binding integrins α3β1 and α6β1, making them able to anchor to the basement 
membrane, whereas melanoma cells show increased levels of integrins αvβ3 and αvβ1, 
allowing them to interact with many ECM proteins of the tumor microenvironment, including 
FN1, von Willebrand factor (vWF), vitronectin, and certain types of collagens (Kuphal et al., 
2005). Integrin αvβ3 is thought to play a particularly important role in melanoma invasion, 
and the increased expression of integrin β3 is one of the changes most highly correlated with 
the transition from RGP to VGP (Seftor, 1998). In addition to supporting migration and 
invasion, integrins have been found to promote tumor progression by regulating anchorage-
independent growth, protecting invading cells from apoptosis, and increasing tumor growth 
(Kuphal et al., 2005). 
Other non-integrin matrix receptors associated with melanoma cell adhesion, migration, or 
invasion include the syndecans and the hyaluronan-binding receptor CD44 (Goebeler et al., 
1996; Lee et al., 2009). In addition to binding to hyaluronan, CD44 is able to bind ECM 
proteins, including COL-I and -VI, FN1, laminin, and SPP1 (Schmidt and Friedl, 2010). 
CD44 also functions as a co-receptor for several other signaling receptors, such as MET, 
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EGFR, and TGFβ receptors. Syndecans, in turn, function as co-receptors for integrins and 
increase the strength of adhesion by binding with their heparin-binding domains to 
glycosaminoglycans, and to other ECM components, including COL-I, -II, -IV, FN1, and 
vitronectin (Schmidt and Friedl, 2010). 
3.1.2 Cell migration 
Depending on the cell and tissue type, cells may migrate individually, using an elongated-
mesenchymal or rounded-amoeboid type of migration, or migrate as a group (collective 
migration) (reviewed in Friedl, 2004). The mesenchymal type of migration is a multistep 
process beginning with the polarization of the cell. The cell forms a leading protrusion, a 
pseudopod, through Cdc42- or Rac-induced localized polymerization of actin filaments. The 
protrusion is stabilized by ECM binding to cell surface receptors, especially β1 and β3 
integrins, and the formation of focal adhesions. Cell-surface proteases (e.g. MT1-MMP and 
urokinase-type plasminogen activator, uPa, see 3.1.3) are recruited to the focal adhesions to 
locally modify the ECM and to create space for the migrating cell. A small GTPase Rho 
activates the main motor protein of non-muscle cells, myosin II, which contracts the actin 
filaments and generates tension inside the cell. Finally, gradual detachment of adhesion 
complexes in the trailing edge allows movement of the cell body towards the leading edge. 
The speed of migration is determined by the strength and turnover rates of the adhesion 
complexes. Stabilization of adhesions reduces migration rates, whereas weakening of 
adhesion strength to intermediate levels results in increased rates of cell migration (Friedl and 
Wolf, 2003). Collective migration is mechanistically similar to mesenchymal single cell 
migration, but instead of detaching adhesions at the trailing cell edge, the leading cell 
maintains its cell-cell adhesion to the following neighbor cell, which is dragged along, as the 
rear of the leading cell is retracted (Friedl, 2004). Amoeboid migration, in contrast, is 
integrin- and protease-independent movement that is driven by weak, non-focalized 
interactions with the ECM, resulting in squeezing of the cell through the ECM barriers 
instead of creating pathways by degradation (Friedl, 2004). All these types of migration have 
been described in melanoma, and melanoma cells have been shown to transit from one 
migration mode to another (reviewed in Orgaz and Sanz-Moreno, 2013). Tumor cells may 
transit from mesenchymal to amoeboid migration when, for example, pericellular proteolysis 
or binding to the ECM is inhibited (Friedl, 2004). 
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3.1.3 Proteolysis of the extracellular matrix 
Degradation of the ECM is an important step in tumor cell invasion. ECM-degrading 
proteases form a tumor-promoting proteolytic interaction network, where the proteolytic 
signals are amplified through reciprocal activation of the proteases and inhibition of 
endogenous protease inhibitors (Mason and Joyce, 2011). In addition to making way for 
invading cells, proteases affect tumor cell proliferation, motility, survival, and angiogenesis 
by liberating growth factors, and generating new biologically active sites and functional 
fragments through ECM remodeling. Proteases may also directly affect intracellular signaling 
through proteolytic activation or inactivation of kinases (reviewed in Lopez-Otin and Hunter, 
2010). The activity of many proteases is reciprocally regulated by phosphorylation (Lopez-
Otin and Hunter, 2010).  
3.1.3.1 Matrix metalloproteinases 
MMPs, members of a large family of zinc-dependent endopeptidases (the metzincins), play 
important roles in several physiological processes, including tissue remodeling, wound 
healing, and inflammation, and are considered to be the most important proteases associated 
with tumor progression (reviewed in Hadler-Olsen et al., 2013; Hofmann et al., 2005; 
Kessenbrock et al., 2010). MMPs are classified according to their substrate specificity and 
cellular localization into five subgroups, including collagenases (degrade fibrillar collagens), 
gelatinases (degrade non-fibrillar and native collagens), stromelysins (degrade proteoglycans 
and glycoproteins), membrane-type MMPs (MT-MMPs), and other MMPs (Fröhlich, 2010; 
Kessenbrock et al., 2010). Most MMPs are soluble secreted proteins consisting of a signal 
peptide, an amino-terminal propeptide, a conserved catalytic domain, a flexible hinge region, 
and a carboxyl-terminal hemopexin-like domain (Kessenbrock et al., 2010). In addition, the 
MT-MMPs contain either transmembrane domains or glycosylphosphatidyl-inositol anchors, 
which allow their localization to the cell surface (Hofmann et al., 2005). The activity of 
MMPs is tightly regulated both through transcriptional and post-transcriptional mechanisms. 
In cancer, increased levels of MMPs are produced both by tumor and stromal cells, especially 
by fibroblasts and macrophages. Melanoma cells have been found to express several MMPs, 
including MMP1, -2, -9, -13, and MT1-MMP (Hofmann et al., 2000). MMPs are expressed in 
a latent form and are proteolytically activated by other MMPs or serine proteases, such as 
plasmin and uPA (Hofmann et al., 2005). The activity of MMPs is further regulated by the 
natural MMP inhibitors α2-macroglobulin, as well as the tissue inhibitors of MMPs (TIMPs), 
which can inhibit both the activation of latent MMPs and the proteolytic function of the 
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mature forms, but in certain situations, may also participate in the activation of MMPs 
(Kessenbrock et al., 2010). In addition, the biological effects of MMPs are determined by 
their localization. In invading cells, several MMPs have been found to interact with cell 
adhesion molecules and to localize to the cell surface to mediate pericellular proteolysis. For 
example, active MMP2 has been reported to bind with its hemopexin domain to integrin αvβ3 
and to facilitate mesenchymal cell invasion (Rupp et al., 2008). Also CD44 has been found to 
interact with active MMP9 and to promote degradation of COL-IV and invasion of tumor 
cells (Yu and Stamenkovic, 1999). Some MMPs may also have non-proteolytic functions, 
such as the activation of intracellular signaling cascades via their hemopexin domain 
(reviewed in Kessenbrock et al., 2010). Despite the important roles MMPs play in tumor 
progression, they have not proven to be ideal therapeutic anti-cancer targets, at least not in 
the treatment of disseminated disease. The failure of broad-spectrum MMP inhibitors may be 
partly due to the elusive non-proteolytic functions of MMPs, as well as the fact that many 
MMPs have dual roles in promoting or inhibiting tumor progression (Hofmann et al., 2005; 
Kessenbrock et al., 2010). 
In addition to the MMPs, some members of the closely related families of the disintegrin and 
metalloproteinases (ADAMs) and the disintegrin and metalloproteinases with 
thrombosbondin motifs (ADAMTSs) have been associated with tumor progression. ADAMs 
are a family of mainly transmembrane proteins, with only half of the members containing 
active metalloproteinase domains (Murphy, 2008). Active ADAMs participate in the 
regulation of inflammation, immune responses, angiogenesis, as well as cell migration and 
proliferation. They function as sheddases, cleaving off extracellular portions of growth factor 
receptors and a wide variety of cell adhesion molecules, such as cadherins, CAMs, and 
CD44, and releasing membrane-bound proforms of cytokines, chemokines and growth 
factors, such as pro-EGF and pro-TNFα (reviewed in Murphy, 2008). ADAMTSs, in turn, are 
secreted metalloproteinases, which in addition to functioning as sheddases, may cleave ECM 
proteins, including aggrecan and VCAN, as well as participate in the maturation of fibrillar 
collagens by cleaving of amino-terminal propeptides (Wagstaff et al., 2011). The role 
ADAMTSs play in tumor progression is less studied, but they appear to have more inhibiting 
than promoting effects (reviewed in Wagstaff et al., 2011). Similarly to MMPs, the activity of 
ADAMs and ADAMTSs is regulated by TIMPs, especially by TIMP3, although the level of 
inhibition is lower than that observed with MMPs (Murphy, 2008; Wagstaff et al., 2011). 
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3.1.3.2 Serine proteases 
Serine proteases are endopeptidases, which play important roles in many physiological 
processes, such as in immune response and blood coagulation, as well as in cancer. One 
important serine protease in tumor progression is plasmin, which exerts its effects by 
degrading various ECM proteins, such as FN1, fibrin, and laminin, and by activating several 
other proteases, including MMPs (reviewed in Dass et al., 2008; Fröhlich, 2010). Plasmin is 
produced by the liver as an inactive form, plasminogen, which is activated through cleavage 
by other serine proteases, the urokinase- and tissue-type plasminogen activators (uPA/PLAU 
and tPA/PLAT) and the coagulation factor XII (Fröhlich, 2010). Of these, also uPA plays an 
important role in tumor progression by promoting angiogenesis, tumor growth, and 
metastasis (Dass et al., 2008). The secreted inactive form of uPA (pro-urokinase) binds to its 
receptor uPAR, anchored to the cell membrane, and is activated by cathepsins as well as 
plasmin, creating a positive feed-back loop of uPA and plasmin activation (Dass et al., 2008). 
Although uPA functions during cell invasion mainly in the pericellular proteolysis in concert 
with integrin-associated uPAR (Smith and Marshall, 2010), also some uPAR-independent 
tumor-promoting effects exist. For example, proteolytically inactive uPA has been found to 
elicit an uPAR-independent mitogenic response in melanoma cells (Koopman et al., 1998). 
The uPA-uPAR activity is regulated primarily by the plasminogen activator inhibitor PAI-1, 
but also by PAI-2, resulting in the internalization and degradation of uPA and recycling of 
uPAR to the cell surface (Dass et al., 2008). PAI-1 has been found to inhibit angiogenesis and 
tumor cell invasion and metastasis, but also in some cases, confusingly, to promote these 
processes (Dass et al., 2008). 
3.1.3.3 Cysteine cathepsins 
Cysteine cathepsins are a family of lysosomal cysteine proteases, acquiring increasing 
attention as important regulators of tumorigenic processes, including angiogenesis and cell 
proliferation and invasion (reviewed in Gocheva and Joyce, 2007; Mohamed and Sloane, 
2006; Turk et al., 2004). The 11 members of this family are produced as inactive precursor 
enzymes that undergo autocatalytic activation in the acidic environment of intracellular 
lysosomes, where they also normally perform their main functions, such as participating in 
protein turnover. In tumors, however, many cathepsins are also found in the cytoplasm or are 
secreted to the extracellular space, where they may function as soluble or membrane-
associated proteases. The cathepsins B and L1 (CTSB and CTSL1), which are considered to 
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be the most important cathepsins in melanoma progression (Fröhlich, 2010), promote 
invasion through several different mechanisms. At the cell surface, they may activate other 
proteases such as uPa (Goretzki et al., 1992; Kobayashi et al., 1993) and MMPs (Eeckhout 
and Vaes, 1977), and disrupt cell-cell adhesion by cleaving E-cadherin (Gocheva et al., 
2006). They can also directly cleave ECM proteins, including laminin, COL-IV, and FN1 
(Buck et al., 1992; Ishidoh and Kominami, 1995). Interestingly, some studies have shown 
that tumor cells, macrophages, and fibroblasts may degrade ECM proteins, such as collagen, 
also intracellularly, involving uPA-uPAR and uPAR associated protein (uPARAP)-dependent 
cellular uptake of collagen and its degradation by cathepsins in lysosomes (Mohamed and 
Sloane, 2006). 
3.2. Micrometastasis formation and metastatic colonization 
After the tumor cells have invaded lymphatic or blood vessels, they need to survive in the 
circulation and to arrest and extravasate into a distant organ. Studies on experimental models 
have suggested that these steps are completed quite efficiently, in contrast to the subsequent 
steps, where survival and growth in the new microenvironment imposes problems to the 
tumor cells, making the last steps of metastasis, i.e. the formation of micrometastases and 
their growth into macrometastases (metastatic colonization), the rate-limiting ones (Cameron 
et al., 2000; Chambers et al., 2002; Fidler, 2003; Luzzi et al., 1998). At the metastatic site, 
tumor cells generally encounter a non-permissive or even a hostile environment, with 
different tissue architecture, types of stromal cells, ECM composition, and a set of growth 
factors compared to the tumor-promoting microenvironment present in the primary tumor 
(Valastyan and Weinberg, 2011). Already in 1889, Stephen Paget suggested with his “seed 
and soil” -theory that disseminated tumor cells (seeds) may form metastases only in organs 
with an environment (soil) permissive to their survival and growth (Fidler, 2003). Today, the 
compatibility between the metastatic cells and the new environment is still considered to be 
essential for the formation of metastases, but the tumor cells are also thought to play a more 
active role in this process by modifying the foreign microenvironments to support their initial 
survival at the metastatic site. Modification of the microenvironment has also been suggested 
to occur even before the dissemination of the cells from the primary tumor through secretion 
of systemic signaling molecules (such as VEGF, TGFβ, and lysyl oxidase) leading to the 
recruitment of tumor-promoting stromal cells to the future sites of metastasis and formation 
of a pre-metastatic niche (Psaila and Lyden, 2009). Although the initial survival of the 
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metastatic cells rarely leads to the formation of macrometastases, the tumor cells may survive 
for long periods of time in a reversible dormancy as single cells or as a micrometastatic tumor 
mass (Chambers et al., 2002). Dormancy may be induced, in addition to the above mentioned 
extrinsic factors, also by intrinsic properties of the disseminated cells, such as the lack of 
sufficient self-renewal capacity (a property of potential tumor stem cells or tumor-initiating 
cells) (Li et al., 2007). Disseminated cells may also be capable of active proliferation, but 
their outgrowth into macroscopic metastases is prevented by increased cell death. Their 
growth may be limited by the immune system (Eyles et al., 2010) or they may suffer from 
increased rates of apoptosis due to an inability to induce angiogenesis (Barnhill et al., 1998; 
Holmgren et al., 1995). Although these several mechanisms have been suggested to regulate 
the dormancy and growth of disseminated cells, the exact molecular factors participating in 
these processes are still largely elusive. Unraveling the exact molecular factors behind the 
outgrowth of metastases is of outmost importance in melanoma, because over 10% of 
melanoma patients are found to have metastatic disease at the time of diagnosis (Pollack et 
al., 2011; Stang et al., 2006). Further, a significant proportion of patients with localized 
disease have occult disseminated cells/metastases already at the time of diagnosis indicated 
by subsequent relapses (see 1.3). In addition, identifying factors regulating dormancy may aid 
in preventing metastasis formation or prolonging tumor-free survival in melanoma, as a 
significant number of patients suffer their first recurrence after a disease-free interval of 10 
years or more (Ossowski and Aguirre-Ghiso, 2010). 
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AIMS OF THE STUDY 
The aim of this study was to identify genes and proteins relevant for the development and 
progression of human cutaneous melanomas by comparing the gene expression profiles of 
benign nevi and melanoma samples (including the stroma) from different stages of the 
disease, and to characterize functionally the most interesting candidate genes and proteins. 
Another aim was to find new diagnostic and prognostic marker molecules as well as potential 
therapeutic targets for detection and treatment of primary and metastatic disease, and to 
develop sensitive RT-PCR and immunohistochemical analyses for early detection of 
melanoma metastases. 
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MATERIALS AND METHODS 
For detailed methods and method references see I-IV. 
4. CELL LINES, PRIMARY CELLS, AND PATIENT SAMPLES (I-IV) 
Human cell lines and primary cells used in this study are presented in Table 2. The BLM cell 
line has been isolated from a lung metastasis formed by BRO melanoma cells inoculated 
subcutaneously into nude mice. 
Table 2. Cell lines and primary cell cultures. 
Name Cell type Publication 
MM170 Metastatic melanoma cell line (lymph node metastasis) IV 
WM115 Primary melanoma cell line (VGP) III, IV  
WM239 Metastatic melanoma cell line (lymph node metastasis) II-IV 
WM793 Primary melanoma cell line (VGP) II-IV 
SKMEL-28 Metastatic melanoma cell line (skin metastasis) I, III, IV 
SKMEL-103 Metastatic melanoma cell line III, IV 
SKMEL-147 Metastatic melanoma cell line III, IV 
BLM Metastatic melanoma cell line (lung metastasis) III, IV 
MDA-MB-231 Primary breast cancer cell line II 
42V Normal melanocytes (primary cell culture) I, IV 
Mela3 Normal melanocytes (primary cell culture) II, IV 
TN-45 Normal melanocytes (primary cell culture) IV 
MEMA EL-29 Primary melanoma cells (primary cell culture) IV 
MEMA MN-24 Primary melanoma cells (primary cell culture) II, IV 
KN-21 Metastatic melanoma cells (primary cell culture) II, IV 
Fibroblast Adult skin fibroblasts (primary cell culture) II-IV 
HES Embryonic skin fibroblasts (primary cell culture) II-IV 
HMVEC Microvascular endothelial cells (primary cell culture) II, IV 
 
Tissue samples of primary skin melanomas (n=133), SLNs from melanoma patients (n=547), 
clinically detected melanoma metastases from lymph nodes (n=59), lung (n=12), and liver 
(n=2), and breast cancer metastases from lymph nodes (n=45), lung (n=2), and liver (n=3), as 
well as non-cancerous lymph nodes (n=28) and benign nevi (n=79) from healthy volunteers 
were collected at the Helsinki University Central Hospital following informed consent and in 
accord with guidelines approved by the local ethics committee (Dnro 208/E5/01 and 
102/2012). Tissue samples were either frozen immediately in liquid nitrogen for RNA 
extraction, confocal microscopy, or immunohistochemistry (IHC), or immersed in RNAlater 
RNA stabilization reagent (Qiagen) for RNA extraction. Paraffin-embedded tissue samples 
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for immunohistochemistry were collected from the archives of the Department of Pathology, 
Helsinki University Central Hospital. 
 
5. RNA ANALYSES (I-IV) 
5.1 Microarray analyses (I-IV) 
Global DNA microarrays are a high-throughput tool for analyzing gene expression changes 
between cells or tissue samples. Total RNAs extracted from cell pellets or frozen/RNAlater-
stabilized tissues by RNeasy Kit (Qiagen) were analyzed using Affymetrix’s Human Genome 
(HG)-U133 set and HG-U133 plus 2.0 arrays, which contain 25-mer oligonucleotide probe 
sets (each consisting of 11 probes) synthesized in situ. The HG-U133 set consists of two 
arrays which together contain almost 45 000 probesets representing over 39 000 transcripts 
corresponding to approximately 33 000 human genes/expressed sequence tags (ESTs). The 
HG-U133 plus 2.0 array contains all the probesets represented in the HG-U133 set arrays as 
well as 9921 additional probesets representing approximately 6 500 genes/ESTs. 
The microarray data were preprocessed with the RMA algorithm (RMAExpress) or with 
MAS 5.0 (Affymetrix Microarray Suite 5.0), and the probe sets were ordered by Significance 
Analysis of Microarrays (SAM). 
 
5.2 Semiquantitative RT-PCR analyses (I-IV) 
The expression levels of various candidate genes were confirmed by semiquantitative RT-
PCR analysis. The primer sequences and cycling conditions are shown in Table 3. The 
numbers of PCR cycles were optimized to be in the linear range. Analysis of β-actin (ACTB) 
levels was used to verify the integrity and equal loading of each mRNA sample. In the 
development of MLANA- and TYR-RT-PCR analyses for detecting melanoma SLN 
micrometastases, the detection limit (approximately 100 melanocytes/melanoma cells in 30 
mg of lymph node tissue) was determined by spiking decreasing numbers of 
melanocytes/melanoma cells into normal lymph node tissue. 
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5.3 Sequencing (II, IV) 
The composition of POSTN splice variants was determined by sequencing PCR fragments 
obtained by using primers that encompassed the alternatively spliced C-terminal region. Also, 
the sequence of the PCR fragments obtained by amplifying the full-length and variant 3 
CTHRC1 mRNA was verified with sequencing. The PCR fragments were separated on high 
resolution MetaPhor agarose (Lonza) and purified with Ultrafree-DA centrifugal filter units 
(Millipore) and with the Illustra GFX PCR DNA and gel band purification kit (GE 
Healthcare). DNA sequencing was performed with the BigDye Terminator v3.1 kit and 3100 
Genetic Analyzer (Life Technologies). 
5.4 Quantitative RT-PCR analysis (II, IV) 
The expression levels of POSTN and CTHRC1 were measured by real-time quantitative RT-
PCR (qRT-PCR) analysis using Taqman Gene Expression assays Hs00170815_m1 and 
Hs00298917_m1 (Life Technologies), respectively. Obtained relative expression values were 
normalized to those of ACTB or ribosomal protein, large, P0 (RPLP0). 
 
6. PROTEIN ANALYSES (I-IV) 
6.1 Immunohistochemistry (I-IV) 
Paraffin-embedded sections (5 µm) were deparaffinized and antigen retrieval was performed 
for vWF, CD31, FN1, pro-collagen-I (PCOL-I), VCAN, TNC, and CTHRC1 staining by 
trypsin treatment, and for POSTN, phospho-SMAD2, SPP1, CTSB, and CTSL1 staining by 
heating the slides in a microwave oven in citrate buffer (pH 6.0) or for TYR and MLANA 
staining in Tris-EDTA buffer (pH 9.0). For both paraffin-embedded and frozen sections, the 
endogenous peroxidase activity was blocked and the sections were incubated with the 
primary antibodies (Table 4) at 4°C overnight. Detection of immunoreactivity was performed 
with the Strept-ABComplex/HRP Duet kit (Dako) or with ChemMate EnVision Detection 
Kit, Peroxidase/DAP, Rabbit/Mouse (Dako) (MLANA and TYR staining). The chromogen 
was either 3,3’-diaminobenzidine (DAB) or 3-amino-9-ethylcarbatzole (AEC), and 
counterstaining was performed with Harris’s or Mayer’s hematoxylin (Merck Millipore).  
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Table 3. Primer sequences and PCR variables. 
Gene 1) 2) Sequence 5’ to 3’ 3) 4) Publication 
ACTB † p F GCTCGTCGTCGACAACGGCTC 55 30 I-IV 
R CAAACATGATCTGGGTCATCTTCTC 
CTHRC1 full-length †† p F AGCGCCTCTGAGATCCCCAA 59 24 IV 
R TGAACAAGTGCCAACCCAGA 
CTHRC1 variant 3 p F AGAAGGTTTAAGGCCGGAAAGGGA 57 35 IV 
R GTCATTTAAGTGAACCATTCCAAGGC 
CTSB p F AAGCTTCGATGCACGGGAACAATG 56 20-25 III 
R TCCAGCCACC ACTTCTGATTCGAT 
CTSL1 p F GTCAGTGTGGTTCTTGTTGG 56 20-25 III 
R AAGGACTCAT GACCTGCATC 
ERBB3 p F TGGCCCTTGAGAGTATCCACTTTG 55 29 I 
R GCCTTCTCCTCCGGTTCATGTATT 
FN1  †††  (EDA domain) p F GGAGAGAGTCAGCCTCTGGTTCAG 56 25 
IV R TGTCCACTGGGCGCTCAGGCTTGTG 
                 (EDB domain) p F CGGCCTGGAGTACAATGTCAGTGT 56 25 
R CAGGTGACACGCATGGTGTCTGGA 
ITGB3 p F GATGCATCCCACTTGCTGGTGTTT 56 23 IV 
R CATTGTTGAGGCAGGTGGCATTGA 
MIA 
p F TGTGCCTTGGTGTCATCATCTTGC 57 25 
I R AGCTCACTGGCAGTAGAAATCCCA 
n F AGTGCAGCCACCCTATCTCCAT 57 14 
R AATCTCCCTGAACGCTGCCT 
MLANA  * 
p F TGACCCTACAAGATGCCAAG 55 30 
I R TCAGCATGTCTCAGGTGTCT 
n F TCATCTATGGTTACCCCAAG 55 21 
R TCATAAGCAGGTGGAGCAT 
NFATC2 p F AAGCCACGGTGGATAAGGACAAGA 56 25 IV 
R ACATGATGTGCTGGAACTCCTGGT 
POSTN p F GTTTGTTCGTGGTAGCACCT 57 32 II 
R TGTTGGCTTGCAACTTCCTCAC 
PRAME  **  
p1 F CTGTACTCATTTCCAGAGCCAGA 55 26 
I 
R TATTGAGAGGGTTTCCAAGGGGTT 
n1 F AGATGGTTTGAGCACAGAGGCAGA 56 14 
R TATTGAGAGGGTTTCCAAGGGGTT 
 
p2 F GTGGCAACAAGTGACTGAGACCTA 57 30 
R GCTTCTTACAGCACAGGCGTAGTA 
n2 F AAATCCAAGCGTTGGAGGTCCTGA 56 16 
R TCTGCCTCTGTGCTCAAACCATCT 
TYR *** 
p F TTGGCAGATTGTCTGTAGCC 55 30 
I R AGGCATTGTGCATGCTGCTT 
n F GTCTTTATGCAATGGAACGC 55 18 
R GCTATCCCAGTAAGTGGACT 
1) p=primary PCR, n=nested PCR; 2) Primer orientation: F=forward, R=reverse; 3) Annealing temperature (°C); 4) Number 
of PCR cycles 
Source of primer sequences: † Life Technologies; †† Park et al. 2013; ††† Tavian et al. 1994; * Palmieri et al. 1999; 
** Ikeda et al. 1997; *** Smith et al. 1991. Other primer pairs have been designed using PrimerQuest 
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6.2 Confocal immunofluorescence microscopy (II) 
 Frozen tissue sections (40-80 µm) were air-dried, blocked with 10% normal horse serum, 
and incubated overnight at room temperature with the primary antibodies (Table 4). 
Immunodetection was performed with Alexa-conjugated (488, 568, or 647) secondary 
antibodies (Life Technologies). Leica DM RXA epifluorescence microscope and Leica TCS 
MP SP confocal microscopy system were used for examining the specimens and the Leica 
TCS NT/SP Scanware for data acquisition and 3D reconstruction imaging.  
 
6.3 Immunofluorescence staining (IV) 
Cells were grown on glass coverslips for two to three days, fixed with 4% paraformaldehyde, 
permeabilized with 0.1% Triton X-100, blocked with 1% bovine serum albumin (BSA) and 
10% normal goat serum, and incubated with the primary antibodies detailed in Table 4. 
Immunodetection was performed with Alexa-conjugated (488 or 594) secondary antibodies 
(Life Technologies), and filamentous actin was immunostained with Alexa Fluor 594-
conjugated phalloidin (Molecular Probes/Life Technologies). Cells were mounted with 
Vectashield H-1200 mounting media containing 4',6-diamidino-2-phenylindole (DAPI) 
(Vector Laboratories). 
 
6.4 Western blotting (I-IV) 
Whole cell lysates, concentrated serum-free conditioned media, and purified/recombinant 
proteins (Table 5) in 1x Laemmli sample buffer were resolved in 8-12% polyacrylamide gels 
and transferred onto nitrocellulose membranes (Bio-Rad). After blocking with 2% BSA, the 
membranes were incubated with primary antibodies (Table 4) overnight at 4°C. 
Immunodetection was performed with horseradish peroxidase-conjugated secondary 
antibodies (Dako) and SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific) or Clarity Western ECL Substrate (Bio-Rad). 
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Table 4. Antibodies. 
Target Antibody* Supplier/Provider Source Method** Publication 
Actin mAb JLA20 EMD Millipore mouse WB III 
α-SMA mAb 1A4 Dako mouse WB III 
β-actin mAb AC-15 Sigma mouse WB III 
CD31 mAb JC70A Dako mouse IHC-Fr II, IV 
COL-I mAb ab6308 Abcam mouse cIF, IHC-Fr II 
CTHRC1 
pAb 11647-RP02 Sino Biological rabbit IF, IHC-Fr 
WB 
IV 
pAb ab85739 Abcam rabbit WB IV 
pAb N2C3 Genetex rabbit IHC-P IV 
CTSB mAb CB 59-4B11 Enzo Life Sciences mouse IHC-P, WB III 
CTSL1 mAb ab7431 Abcam mouse IHC-P III 
 pAb D20 Santa Cruz Biotechnology goat WB III 
FN1 
mAb NCL-FIB (clone 
568) 
Leica Biosystems mouse IHC-P II 
pAb ab23516 Abcam sheep cIF II 
pAb F3648 Sigma-Aldrich rabbit WB II, IV 
mAb L8 Santa Cruz Biotechnology mouse FB II 
FN1 EDA+ 
(cellular) 
mAb FN-3E2 Sigma-Aldrich mouse IHC-Fr II, IV 
HGF pAb R&D Systems goat WB III 
ITGB3 pAb H-96 Santa Cruz Biotechnology rabbit WB IV 
LAMP1 mAb H4A3 Santa Cruz Biotechnology mouse IF IV 
MLANA mAb  coctail A103/ M2-7C10/ M2-9E3 
Life Technologies mouse IHC-P I 
mAb A103 Life Technologies mouse cIF II 
PCOL-I mAb M-58 Millipore rat IHC-P II 
POSTN 
pAb RD181045050 Biovendor rabbit cIF, IHC-Fr, IHC-P, 
WB 
II 
pAb S-15 Santa Cruz Biotechnology goat WB II 
phospho-SMAD2 pAb AB3849 Millipore rabbit IHC-P II 
Reticular 
fibroblasts/fibers 
mAb ER-TR7 Acris Antibodies rat IHC-Fr II 
SPP1 mAb 53 Dr. A. Chambers, University of 
Western Ontario
mouse IHC-P I 
TGFβ mAb R&D Systems mouse FB, WB III 
TGOLN2 mAb 2F7.1 Novus Biologicals mouse IF IV 
TNC mAb BC-24 Abcam mouse cIF II 
α-tubulin mAb DM1A Abcam mouse WB IV 
pAb Rockland Immunochemicals rabbit WB III 
TYR mAb NCL-TYROS 
(clone T311) 
Leica Biosystems mouse IHC-P I 
VCAN mAb 2B1 Seikagu Corporation mouse IHC-P II 
vWF pAb A0082 Dako rabbit IHC-P II, IV 
* mAb=monoclonal antibody; pAb=polyclonal antibody 
** cIF=confocal immunofluorescence microscopy, FB=function blocking,  IF=immunofluorescence staining, IHC-Fr= 
immunohistochemistry on frozen sections, IHC-P=immunohistochemistry on paraffin-embedded sections, WB=Western blot 
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6.5 Surface plasmon resonance analysis (II) 
Binding of purified and recombinant human proteins (detailed in Table 5) to each other was 
analyzed with the Biacore 2000 surface plasmon resonance -based biosensor. This method 
allows analyzing the specificity, kinetics, and affinity of interactions between molecules in 
real-time. All proteins studied were used both as the ligand coupled to the CM5 sensor chip 
surface using the standard amine coupling kit (Biacore) and as the soluble analyte injected 
over the coated surfaces. Non-specific binding to an uncoated control surface was subtracted 
from the binding to the protein-coated surfaces and the interactions were analyzed with the 
BIAevalution 3.1 Software (Biacore). 
 
Table 5. Purified or recombinant proteins. 
Protein Source Supplier Method* Publication 
COL-I purified from rat tail BD Biosciences A, M II, IV 
CTHRC1 recombinant produced in human cells Sino Biological A IV 
CTSB purified from human liver Merck/Calbiochem WB III 
CTSL1 purified from human liver Merck/Calbiochem WB III 
cFN purified from human foreskin 
fibroblasts 
United States 
Biological 
A, I, M II, IV 
pFN purified from human plasma Millipore A, SPR II, IV 
POSTN  recombinant, full-length produced in a mouse myeloma 
cell line (NS0) 
R&D Systems A, I, M, 
SPR 
III 
               recombinant, 75 kDa fragment produced in E.coli Biovendor A, M, 
SPR 
III 
TGFβ1, recombinant produced in human cells Humanzyme C III 
TNC purified from a human glioma 
cell line (U251) 
Millipore A II, IV 
SPP1  recombinant produced in a mouse myeloma 
cell line (NS0) 
R&D Systems SPR II 
*A=Adhesion assay; C=Cell culture; I=Cell invasion assay (Matrigel); M=Cell migration assay; SPR=Surface plasmon 
resonance; WB=Western blot 
 
7. FUNCTIONAL ANALYSES (II-IV) 
7.1 Transduction with shRNA lentiviral particles (II, IV) 
To study the effects of knocking down FN1, POSTN, and CTHRC1 expression in melanoma 
cells, endothelial cells, and/or fibroblasts, the cells were transduced with lentiviral particles 
(Santa Cruz Biotechnology) targeting the respective molecules (FN1: sc-29315-V; POSTN: 
sc-61324-V; CTHRC1: sc-77043-V), or with negative control short hairpin RNA (shRNA) 
particles (sc-108080). Puromycin-resistant pools were used in the following experiments. 
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7.2 Transfection of siRNA oligonucleotides (IV) 
To further study the effect and expression of CTHRC1, we also knocked down CTHRC1 
expression in melanoma cells by transfecting them with small interfering RNAs (siRNAs) 
targeting all CTHRC1 isoforms (sc-77043) and with scrambled control siRNAs (sc-37007, 
both from Santa Cruz Biotechnology), as well as with siRNAs targeting only the full-length 
or the variant 3 CTHRC1 (both designed using the Integrated DNA Technologies RNAi 
Design Tool and manufactured by Integrated DNA Technologies).  
7.3 Fluorescent labeling of living cells (III) 
Cells were grown overnight in growth medium and washed once with serum-free medium 
before labeling with 5 or 10 µmol/L Celltracker Green CMFDA or Red CMTPX (Life 
Technologies) in serum-free medium for 45 minutes at 37°C in 5% CO2. Labeled cells were 
grown overnight in normal growth medium before using in assays. 
7.4 Cell adhesion assay (II, IV) 
The adhesion of cells to uncoated surfaces or surfaces coated with 1µg (10 µg/ml) of selected 
proteins (Table 5) or protein combinations was tested on 96-well plates. Cells were added to 
the washed wells in serum-free medium and allowed to attach for 1 hour and 15 minutes (± 
15  minutes), after which the cells were photographed and counted. Fatty-acid free, low 
endotoxin BSA served as a control coating. 
7.5 Cell migration assay (II, IV) 
Falcon cell culture inserts (8 µm, BD Biosciences) were used to study the migration of cells 
on uncoated or protein-coated surfaces (proteins used for the coatings are presented in Table 
5). The inner surface of the insert membrane was coated with 40 µl of 90 µg/ml protein and 
the outer surface with 40 µl of 45 µg/ml protein to facilitate the attachment of migrated cells 
in serum-free medium. Cells were added to the inserts in serum-free medium, and the lower 
chamber was filled with serum-free medium (with coated surfaces) or medium supplemented 
with 10% FBS (fetal bovine serum) (with uncoated surfaces). The cells were fixed after 16- 
to 42-hour incubation and stained with 0.5% crystal violet (in 20% methanol). Cells were 
scraped off from the inner surface of the insert membrane, and the migrated cells on the outer 
surface of the membrane were photographed and counted. Statistical significance was tested 
by two-tailed t-test. 
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7.6 Three-dimensional collagen gel and Matrigel invasion assays (II-IV) 
The ability of melanoma cells to invade in vitro was studied in 3D collagen gel (collagen-I, 
high concentration, rat tail) and growth factor-reduced Matrigel (both from BD Biosciences). 
Cells were plated between two thick gel layers and growth medium supplemented with 10% 
FBS was added on top of the gels. In the invasion analyses of the co-cultured melanoma cells 
and fibroblasts, equal amounts of cells were either mixed before seeding between the two gel 
layers or were co-cultured separately in the middle and the top of the gel. In addition, to study 
the effect of selected proteins on cell invasion, recombinant/purified proteins (Table 5), 
inhibitors (Table 6), or neutralizing antibodies (Table 4) were added to the lower and upper 
gel layers as well as to the growth medium. The invasion of cells was followed daily by 
microscopy and photography. 
Table 6. Inhibitors. 
Inhibitor Target Inhibitor concentration Publication 
Cyclosporin A Calcineurin/NFAT 0.1-4 µM IV 
BB-2516 MMPs 10 µM III 
BB-3103 MMPs 10 µM III 
GM6001 MMPs 10 µM III 
GSK2118436A Mutant BRAF 2-20 nM IV 
CA-074 CTSB 5 µM III 
CA-074 Me CTSB 5 µM III 
Z-FF-FMK CTSL 15 µM III 
Z-FY-CHO CTSL 15 µM III 
SB-505124 TGFβRI (ALK5) 1-5 µM III, IV 
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RESULTS AND DISCUSSION 
8. GENE EXPRESSION CHANGES IN DIFFERENT STAGES OF 
MELANOMA PROGRESSION (I-IV) 
In order to reveal genes and proteins associated with the development and progression of 
melanomas, and to find new potential diagnostic and prognostic markers, we compared the 
whole-genome expression profiles of benign nevi and melanoma tissue samples from 
different stages of the disease. All tissue samples contained the adjacent stromal 
compartment, allowing also the detection of changes occurring in the tumor stroma. Our goal 
was to find potential gene expression changes that are common among the heterogeneous 
melanomas, thus providing better markers and rational therapeutic targets. 
8.1 Primary melanoma development 
To identify genes potentially involved in the development of melanomas, we analyzed the 
global gene expression profiles of benign nevi (n=11) and primary melanomas (n=21) with 
Affymetrix HG-U133 plus 2.0 oligonucleotide microarrays. We found 1058 genes with 
specific annotations to be significantly up-regulated and 732 genes to be down-regulated 
(≥1.5-fold) in the primary melanomas (IV: Supplemental Tables S1 and S2; topmost genes 
with ≥2-fold changes) by SAM analysis. Among the most significantly up-regulated genes 
were serglycin (SRGN), a gene found to associate with the aggressive phenotype of tumor 
cells and to promote inflammation (Korpetinou et al., 2014), and karyopherin α2 (KPNA2), a 
proposed tumor marker in several cancers (Christiansen and Dyrskjot, 2013). Some of the up-
regulated genes have been linked to melanoma development in two earlier studies that used 
older and less comprehensive microarray platforms. For example, we found in our study 101 
of the 167 genes reported by Mauerer et al. (Mauerer et al., 2011) to be up-regulated in 
primary melanomas compared to benign nevi (Figure 7). Among these genes were the ECM-
protein encoding genes COL4A1 (fold 3.3), TNC (fold 3.0), and FN1 (fold 2.2), the 
melanoma antigen PRAME (fold 8.1), the anti-apoptotic BCL2A1 (fold 3.6), cytokines 
CXCL9 (fold 8.6) and GDF15 (fold 4.0), as well as the multifunctional cytokine-like SPP1 
(fold 50.2). We further found 42 up-regulated genes in common with the study by Talantov et 
al. (Talantov et al., 2005) (Figure 7). In addition to SPP1, BCL2A1, and GDF15, common 
genes included many genes involved in cell cycle or DNA replication and repair, such as 
RRM2 (fold 3.8), CKS2 (fold 4.2), CCNB1 (fold 2.9), and  TOP2A (fold 4.4). Inspection of 
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our gene list for over 4-fold changes showed especially the calcium-binding proteins 
S100A8, S100A7, and S100A9 to be highly and significantly up-regulated in melanomas. 
Although the S100B protein has been studied extensively as a melanoma marker (Harpio and 
Einarsson, 2004), S100A proteins have been less studied in melanoma. S100 proteins 
regulate many processes involved in cancer development and progression, such as cell 
growth and motility (reviewed in Heizmann et al., 2002), warranting a more detailed study 
about the relevance of these proteins in melanoma. Other highly up-regulated genes in 
melanoma development were microRNA 21 (MIR21), CTHRC1, and CXCR4. MIR21 and 
CXCR4 have been suggested to be prognostic factors for melanoma (Jiang et al., 2012; 
Toyozawa et al., 2012), and CTHRC1 has been found to be up-regulated in invasive 
melanomas (Tang, 2006). 
 
 
To further search for genes more specifically associated with early melanoma development, 
we compared the gene expression profiles of benign nevi (n=11) and thin primary melanomas 
(Breslow’s thickness <2.0 mm; n=9). SAM resulted in 1293 probesets representing 936 genes 
up-regulated and 834 probesets representing 593 genes down-regulated (≥1.5-fold) in thin 
melanomas (the topmost ≥4-fold up-regulated genes are shown in Table 7). The most 
significantly up-regulated gene was fatty acid binding protein 5 (FABP5; fold 4.3), which has 
not been linked to melanoma development, but has been suggested to associate with the 
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progression of other cancers, such as breast cancer (Liu et al., 2011), oral squamous cell 
carcinoma (Fang et al., 2010), and intrahepatic cholangiocarcinoma (Jeong et al., 2012). The 
most significantly down-regulated gene, in turn, was glioma tumor suppressor candidate 
region gene 2 (GLTSCR2; fold 1.8), which has been suggested to be a tumor suppressor 
involved in the DNA damage response (Kim et al., 2011). This gene has not been linked to 
melanoma development previously, but it suggests that genomic instability may play a role in 
early melanoma development. 
As also the smaller changes in gene expression can have an effect on cell behavior when they 
are combined in pathways, we searched if any pathways are enriched among the genes up-
regulated (≥1.5-fold) during the early development of melanoma. We found especially the 
Gene Ontology (GO) terms RNA splicing (GO:0008380; p= 1.5e-06) and immune response 
(GO:0006955; p=5.5e-06) as well as the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathway ECM-receptor interaction (ID 04512; p=0.000361) to be significantly 
enriched. Aberrant and alternative RNA splicing is known to play an important role in cancer 
development (reviewed in Fackenthal and Godley, 2008; Venables, 2004), and the genes 
involved in RNA splicing may also provide potential targets for the treatment of melanomas. 
The immune response pathway, in turn, may be up-regulated in melanoma development as an 
anti-tumor response or as a part of the formation of a pro-inflammatory microenvironment 
(see 2.1.4). Also changes in the interactions between the tumor cells and the ECM are known 
to play an important role in tumor development (see Figure 6). 
We were further interested to find out which genes are specifically up-regulated in melanoma 
cells, so we checked the expression levels of the up-regulated genes in isolated melanoma 
cells and melanocytes (Table 8). The most highly up-regulated gene in melanoma cells was 
CTHRC1 (not presented in the HG-U133 A 2.0 array used by Mauerer et al. or in the HG-
U133 A array used by Talantov et al.), encoding a protein first found to be expressed by 
fibroblasts and smooth muscle cells in injured arteries (Pyagay et al., 2005). 
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Table 7. The topmost significantly over-expressed (≥4-fold) genes* in thin primary melanomas 
(Breslow’s thickness <2 mm) compared to benign nevi by Significance Analysis of Microarrays 
(SAM). 
   Mean ± Stdev  Melanomas vs nevi 
Gene Gene description Probeset ID 
Benign nevi 
(n=11) 
Thin 
melanomas 
(n=9) 
 Fold 
SAM 
score
** 
FABP5 Fatty acid binding protein 5 202345_s_at 2088 ± 565 8975 ± 2752  4.3 7.993 
S100A7 S100 calcium binding protein A7 205916_at 1641 ± 1022 9501 ± 3947  5.8 6.304 
S100A8 S100 calcium binding protein A8 202917_s_at 1961 ± 1327 11616 ± 4841  5.9 6.300 
GJB2 Gap junction protein, beta 2 223278_at 570 ± 451 2595 ± 1233  4.6 4.882 
MIR21 MicroRNA 21 224917_at 127 ± 75 857 ± 450  6.7 4.780 
TRIM22 Tripartite motif containing 22 213293_s_at 287 ± 116 1179 ± 560  4.1 4.754 
SERPINB3 Serpin peptidase inhibitor, clade B, member 3 209720_s_at 159 ± 84 1703 ± 1063  10.7 4.602 
S100A9 S100 calcium binding protein A9 203535_at 339 ± 155 4953 ± 3754  14.6 4.041 
SERPINB4 Serpin peptidase inhibitor, clade B, member 4 211906_s_at 48 ± 51 963 ± 758  19.9 3.756 
GBP1 Guanylate binding protein 1, interferon-inducible 202270_at 135 ± 97 946 ± 707  7.0 3.531 
CD24 CD24 molecule 208650_s_at 228 ± 133 957 ± 620  4.2 3.529 
MIR612 MicroRNA 612 227062_at 953 ± 549 4379 ± 3229  4.6 3.424 
CD36 CD36 molecule 228766_at 87 ± 105 795 ± 675  9.1 3.204 
MPZL2 Myelin protein zero-like 2 203780_at 172 ± 105 713 ± 509  4.1 3.140 
CSRP2 Cysteine and glycine-rich protein 2 207030_s_at 224 ± 104 908 ± 666  4.0 3.135 
UBE2D3 Ubiquitin-conjugating enzyme E2D 3 240383_at 68 ± 47 314 ± 215  4.6 3.004 
CXCL9 Chemokine (C-X-C motif) ligand 9 203915_at 128 ± 39 1589 ± 1574  12.4 2.997 
SLC6A14 Solute carrier family 6 (amino acid transporter), member 14 219795_at 49 ± 50 229 ± 139  4.7 2.975 
SERPINB13 Serpin peptidase inhibitor, clade B, member 13 217272_s_at 341 ± 192 1595 ± 1378  4.7 2.892 
STAT1 Signal transducer and activator of transcription 1, 91kDa 209969_s_at 98 ± 55 468 ± 371  4.8 2.886 
CCL18 Chemokine (C-C motif) ligand 18 32128_at 220 ± 177 2531 ± 2652  11.5 2.845 
S100A7A S100 calcium binding protein A7A 232170_at 53 ± 11 226 ± 154  4.2 2.789 
SEMA6A Semaphorin 6A 215028_at 34 ± 17 452 ± 454  13.2 2.753 
RGS1 Regulator of G-protein signaling 1 216834_at 29 ± 29 457 ± 471  15.9 2.730 
CXCR4 Chemokine (C-X-C motif) receptor 4 217028_at 65 ± 33 328 ± 268  5.0 2.713 
XAF1 XIAP associated factor 1 228617_at 185 ± 145 751 ± 625  4.1 2.710 
CXCL10 Chemokine (C-X-C motif) ligand 10 204533_at 76 ± 15 1291 ± 1456  17.0 2.688 
FAM26F Family with sequence similarity 26, member F 229390_at 53 ± 23 299 ± 255  5.6 2.662 
* Only annotated genes and the first probe set for each gene are shown. 
**False-discovery rate (FDR) q-value was <0.0001 for all genes. 
  
 
Table 8. Genes over-expressed (fold ≥ 3) both in primary melanoma compared to benign nevi tissues and in cultured primary melanoma cells compared to 
normal melanocytes. 
   Mean ± StDev Melanoma cells vs melanocytes 
Primary melanomas 
vs benign nevi 
Gene Gene description Probe set ID Normal melanocytes (n=3) 
Primary melanoma 
cells (n=3) Fold 
SAM 
score Fold 
CTHRC1 Collagen triple helix repeat containing 1 225681_at 34.6 ± 10.7 1713.4 ± 1177.8 49.5 3.791 4.1 
GDF15 Growth differentiation factor 15 221577_x_at 85.3 ± 61.4 2007.8 ± 3070.6 23.5 1.784 4.0 
PRAME Preferentially expressed antigen in melanoma 204086_at 29.2 ± 5.3 627.8 ± 359.4 21.5 2.836 8.1 
THBS1 Thrombospondin 1 201109_s_at 19.7 ± 1.4 280.4 ± 387.6 14.2 2.093 3.6 
IGFBP2 Insulin-like growth factor binding protein 2, 36kDa 202718_at 29.8 ± 1.7 418.2 ± 431.9 14.0 2.098 3.0 
SLC20A1 Solute carrier family 20, member 1 201920_at 158.5 ± 75.1 1509.8 ± 1700.4 9.5 3.102 3.8 
MIR21 MicroRNA 21 224917_at 75.1 ± 9.7 616.3 ± 230.9 8.2 4.267 10.4 
PRR11 Proline rich 11 228273_at 56.5 ± 31.4 432.8 ± 140.1 7.7 2.628 3.3 
TOP2A Topoisomerase (DNA) II alpha 170kDa 201291_s_at 32.8 ± 21.5 244.0 ± 225.9 7.4 2.193 4.4 
NNMT Nicotinamide N-methyltransferase 202237_at 35.0 ± 2.7 258.8 ± 127.5 7.4 2.408 5.7 
PBK PDZ binding kinase 219148_at 33.0 ± 22.1 241.6 ± 148.9 7.3 2.446 4.5 
ASPM Asp (abnormal spindle) homolog, microcephaly associated 219918_s_at 40.6 ± 21.7 287.8 ± 151.8 7.1 2.386 4.4 
CYR61 Cysteine-rich, angiogenic inducer, 61 201289_at 50.9 ± 2.0 348.1 ± 202.5 6.8 2.905 3.3 
ADAM12 ADAM metallopeptidase domain 12 226777_at 25.8 ± 2.9 142.4 ± 158.4 5.5 2.360 6.1 
LOC541471 Hypothetical LOC541471 225799_at 117.5 ± 12.2 558.6 ± 130.6 4.8 3.432 4.7 
AURKA Aurora kinase A 208079_s_at 65.2 ± 32.3 308.1 ± 133.9 4.7 1.853 3.5 
SPP1 Secreted phosphoprotein 1 209875_s_at 78.0 ± 39.8 360.9 ± 523.6 4.6 2.718 50.2 
RRM2 Ribonucleotide reductase M2 209773_s_at 257.8 ± 358.3 1140.9 ± 567.3 4.4 2.959 3.8 
CCL2 Chemokine (C-C motif) ligand 2 216598_s_at 62.3 ± 4.7 258.8 ± 308.5 4.2 1.697 4.6 
CKS2 CDC28 protein kinase regulatory subunit 2 204170_s_at 130.8 ± 124.4 515.8 ± 253.7 3.9 2.895 4.2 
LAMA1 Laminin, alpha 1 227048_at 36.0 ±15.0 137.2 ± 83.0 3.8 1.713 5.3 
KIAA0101 KIAA0101 202503_s_at 227.0 ± 277.6 683.0 ± 320.9 3.0 4.052 3.4 
Only annotated genes and the first probe set for each gene are shown. 
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8.2 Primary melanoma invasion 
To search for genes associated with primary melanoma invasion/progression, we compared 
the gene expression profiles of thin (Breslow’s thickness <2.0 mm; n=9) and thick (>2 mm; 
n=11) primary melanomas. The use of 2 mm cut-off is supported by the study of Riker et al. 
(Riker et al., 2008) where average Breslow’s tumor thickness of 2.1 mm was found to be the 
point where the gene expression profiles of primary melanomas showed a marked change 
towards the gene expression profiles of melanoma metastases. Our SAM analysis resulted in 
918 probesets representing 671 annotated genes up-regulated and 1078 probesets representing 
806 genes down-regulated (≥1.7-fold) in thick primary melanomas. The topmost significantly 
over-expressed genes (≥2-fold) are presented in Table 9. One of the most highly up-regulated 
genes was SPP1, which has been found to correlate with primary melanoma invasion (Zhou 
et al., 2005) and to promote the invasive growth of melanoma cells in 3D matrices (Yin et al., 
2014). Another up-regulated gene, tensin 3 (TNS3), has been found to enhance the growth 
and migration of melanoma cells in vitro (Qian et al., 2009). In addition, sushi-repeat 
containing protein, X-linked (SRPX2) may also play a role in melanoma cell invasion as it 
has been found to promote cell migration and adhesion in gastric cancer cells (Tanaka et al., 
2009). When we compared our gene list with an earlier study on gene expression changes 
between thin and thick primary melanomas (Jaeger et al., 2007), we found a markedly larger 
set of genes to be significantly differentially expressed. Jaeger et al. found only 27 genes to 
be up-regulated in thick (>2mm Breslow) compared to thin (<1 mm Breslow) primary 
melanomas [genes in common with our study were BCL2A1 (fold 2.9), CDH19 (fold 3.8), 
and ETV1 (fold 3.7)]. However, they used a smaller Affymetrix platform (HG-U133 A) 
presenting approximately half of the genes found in the HG-U133 plus 2.0 array we used. 
Further, they used laser-capture microdissection to isolate the tumor cells from the stroma, 
suggesting that many of the gene expression changes found in our study may be of stromal 
origin. In concordance with this, many of the most significantly up-regulated genes in our 
study (Table 9) have been reported to be also expressed by stromal cells. For example, 
TIMP1 has been found to be over-expressed by both tumor and stromal cells in invasive 
melanomas (Airola et al., 1999), and high expression of stromal LGALS1 in prostate cancer 
has been reported to be a strong predictor of poor patient outcome (van den Brule et al., 
2001). Also, high SULF1 expression in the stroma of gastric cancer is associated with a more 
aggressive tumor phenotype and predicts poor survival (Hur et al., 2012). In turn, up-
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regulation of the basement membrane type collagen-IV (COL4A1) may indicate increased 
formation of blood vessels e.g. angiogenesis in the invasive melanomas. 
Also among the up-regulated genes was SLC2A3, a glucose transporter, which is also over-
expressed in endometrial and breast cancer, especially in poorly differentiated tumors 
(Krzeslak et al., 2012). In addition, over-expression of SLC2A3 is associated with poor 
survival in non-small cell lung cancer (Younes et al., 1997) and in laryngeal carcinoma. Up-
regulation of this gene may increase uptake of glucose, the primary energy source of tumor 
cells. Also FLOT1, a caveolae-associated integral membrane protein, may play a role in 
melanoma progression, as its over-expression has been found to correlate with advanced 
clinical stage and poor survival in lung adenocarcinoma (Zhang et al., 2012) and breast 
cancer (Lin et al., 2011). Further, over-expression of a highly homologous gene FLOT2 has 
been associated with progression of melanomas (Hazarika et al., 2004).         
As proteolysis of the ECM is an important step in tumor cell invasion (see 3.1.3), we checked 
the list of genes up-regulated in thick melanomas specifically for proteases. The most 
significantly over-expressed proteases were membrane metalloendopeptidase (MME), AE 
binding protein 1 (AEBP1), CTSL1, CTSB, PLAT, PLAU, and ADAM12 (III: Table 2). 
Interestingly, specific MMPs seem to be expressed in only some melanomas, as only MMP3, 
MMP1, MMP9, and MMP16 were up-regulated with low SAM scores (<1.6) (data not 
shown). Also, in a comparison between benign nevi and thin primary melanomas, cathepsins 
C and S, ADAM9, ADAMTS2, and FAP got higher SAM scores than the only significantly up-
regulated MMP gene, MMP9 (data not shown). In subsequent functional studies, we 
concentrated especially on studying the relevance of cathepsins B and L1 in melanoma 
invasion.
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Table 9. The topmost significantly over-expressed (≥2-fold) genes* in thick (>2 mm) compared to 
thin (<2 mm) primary melanomas by Significance Analysis of Microarrays (SAM). 
   Mean ± StDev  Thick vs thin melanomas 
Gene Gene description Probe set ID 
Thin 
melanomas 
(n=9) 
Thick 
melanomas 
(n=11) 
 Fold SAM score* 
TIMP1 TIMP metallopeptidase inhibitor 1 201666_at 1810 ± 747 6247 ± 2122  3.5 5.822 
LGALS1 Lectin, galactoside-binding, soluble, 1 201105_at 3724 ± 956 9211 ± 3105  2.5 5.008 
GNS Glucosamine (N-acetyl)-6-sulfatase 212334_at 1028 ± 245 2097 ± 644  2.0 4.369 
PLEKHO2 Pleckstrin homology domain containing, family O member 2 204436_at 319 ± 93 741 ± 248 
 2.3 4.051 
LOC541471 Hypothetical LOC541471 225799_at 480 ± 272 1413 ± 615  2.9 3.915 
TNS3 Tensin 3 217853_at 761 ± 203 1590 ± 561  2.1 3.871 
SULF1 Sulfatase 1 212354_at 177 ± 68 545 ± 227  3.1 3.858 
SLC2A3 Solute carrier family 2, member 3 202499_s_at 115 ± 58 466 ± 218  4.0 3.816 
ARPC1B Actin related protein 2/3 complex, subunit 1B, 41kDa 201954_at 1220 ± 528 3300 ± 1603 
 2.7 3.607 
SERPINB6 Serpin peptidase inhibitor, clade B, member 6 211474_s_at 370 ± 81 804 ± 303 
 2.2 3.588 
SRPX Sushi-repeat-containing protein, X-linked 204955_at 822 ± 356 1672 ± 584 
 2.0 3.546 
DAB2 Disabled homolog 2, mitogen-responsive phosphoprotein 201279_s_at 702 ± 363 1655 ± 684 
 2.4 3.524 
SERPINE2 Serpin peptidase inhibitor, clade E, member 2 212190_at 2579 ± 2393 7341 ± 3395 
 2.8 3.498 
SLC20A1 Solute carrier family 20, member 1 201920_at 464 ± 244 1304 ± 639  2.8 3.460 
MME Membrane metallo-endopeptidase 203435_s_at 181 ± 53 421 ± 150  2.3 3.448 
ARHGEF40 Rho guanine nucleotide exchange factor (GEF) 40 58780_s_at 238 ± 71 554 ± 216 
 2.3 3.429 
SPP1 Secreted phosphoprotein 1 209875_s_at 283 ± 222 3791 ± 3024  13.4 3.400 
C13orf18 Chromosome 13 open reading frame 18 219471_at 162 ± 66 328 ± 78 
 2.0 3.340 
COL4A1 Collagen, type IV, alpha 1 211981_at 494 ± 212 1007 ± 365  2.0 3.325 
FLOT1 Flotillin 1 208749_x_at 730 ± 147 1518 ± 646  2.1 3.320 
RNASE1 Ribonuclease, RNase A family, 1 (pancreatic) 201785_at 1472 ± 752 4160 ± 2283 
 2.8 3.301 
HEY1 Hairy/enhancer-of-split related with YRPW motif 1 44783_s_at 514 ± 303 1674 ± 973 
 3.3 3.266 
MMPPED2 Metallophosphoesterase domain containing 2 205413_at 26 ± 8 150 ± 64 
 5.7 3.209 
HOXB7 Homeobox B7 204779_s_at 246 ± 106 529 ± 195  2.2 3.170 
SH2B3 SH2B adaptor protein 3 203320_at 266 ± 126 629 ± 269  2.4 3.169 
HEXA Hexosaminidase A 201765_s_at 583 ± 97 1295 ± 626  2.2 3.117 
LOXL2 Lysyl oxidase-like 2 202998_s_at 226 ± 93 452 ± 144  2.0 3.111 
PLAUR Plasminogen activator, urokinase receptor 210845_s_at 177 ± 75 519 ± 270  2.9 3.109 
ZCCHC24 Zinc finger, CCHC domain containing 24 212423_at 566 ± 133 1209 ± 559  2.1 3.085 
LOC151162 
/ MGAT5 
Hypothetical LOC151162 / mannosyl 
(alpha-1,6-)-glycoprotein beta-1,6-N-
acetyl-glucosaminyltransferase 
212098_at 595 ± 168 1302 ± 616  2.2 3.081 
SGCE Sarcoglycan, epsilon 204688_at 150 ± 56 470 ± 255  3.1 3.080 
SRGN Serglycin 201858_s_at 730 ± 442 1907 ± 1018  2.6 3.076 
*Only annotated genes and the first probe set for each gene are shown. 
**FDR q-value was <0.0001 for all genes. 
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8.3 Melanoma metastasis 
Although the Breslow’s thickness of the primary melanoma is considered to be the most 
important factor in assessing the risk of developing metastatic disease, a significant portion of 
thin melanomas metastasize (Murali et al., 2012). In order to search for new molecular 
indicators/markers of metastatic potential, we compared the gene expression profiles of non-
metastatic (n=8; minimum follow-up of 53 months) and metastatic (n=12) primary 
melanomas by HG-U133 plus 2.0 arrays. SAM resulted in 1050 probesets representing 787 
genes up-regulated  and 1517 probesets representing 1133 genes down-regulated  (≥1.5-fold) 
(IV: Supplemental Tables S3 and S4; topmost genes with ≥2-fold changes) in the metastatic 
primary melanomas. Among the most up-regulated genes were, for example, HEY1, a 
mediator of notch signaling, and homeobox B7 (HOXB7), that has been suggested to promote 
growth and invasion of tumor cells and serve as a prognostic factor in several cancers (Liao et 
al., 2011; Nguyen Kovochich et al., 2013; Yuan et al., 2014). In an earlier study, Alonso et al. 
(Alonso et al., 2007) recognized (by using a small cDNA microarray platform OncoChip) 
especially EMT-related genes to be significantly associated with metastasis development in 
melanoma. Of those genes, we found among others genes encoding a cell surface 
glycoprotein CD63 (fold 1.7), an ECM protein LUM (fold 1.5), a protease CTSB (fold 1.6), a 
serine protease inhibitor SERPINA3 (fold 2.4), and a membrane protein EMP1 (fold 1.8) to 
be up-regulated in the metastatic primary melanomas. Conway et al., in turn, analyzed the 
expression of 502 cancer-related genes in primary melanomas and found 13 genes to be 
associated with reduced relapse-free survival (Conway et al., 2009). Here, we found four of 
those genes to be up-regulated in the metastatic primary melanomas, including SPP1 (fold 
12.6), TOP2A (fold 1.9), and TK1 (1.7), as well as a gene encoding the apoptosis inhibitor 
BIRC5 (1.8). In another study, genes involved in DNA replication and repair pathways were 
found to be associated with metastatic dissemination of melanomas (Kauffmann et al., 2008; 
Winnepenninckx et al., 2006). We found a concordant result among others for RRM2 (fold 
2.3), PTTG1 (1.7), CKS2 (fold 2.1), CCNB1 (fold 1.7), and TOP2A (fold 1.9). It seems that 
many different pathways may be activated in the development of metastatic traits in 
melanoma. In our dataset especially genes involved in signaling (p=3.5e-10), cell adhesion 
(p=6.9e-10), positive regulation of immune system process (p=1.2e-09), locomotion (p=2.5e-
09), vasculature development (p=3.4e-08), ECM disassembly (p=4.1e-08), and  ECM 
organization (p=6.3e-08) (GO classes), as well as ECM-receptor interaction (p=1.0e-06) and 
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focal adhesion (p=5.0e-06) (KEGG pathways) were up-regulated in the metastatic primary 
tumors, suggesting that also changes in the tumor microenvironment play an important role in 
melanoma metastasis. 
When we compared the list of genes up-regulated in the metastatic melanomas to the genes 
up-regulated in thick compared to thin melanomas, in addition to many genes mentioned 
above (including SPP1, FLOT1, LGALS1, SULF1, and COL4A1), the most interesting genes 
potentially more significantly associated with metastasis and not just tumor thickness were 
VCAN, TIMP3, and CTHRC1. All these three genes have been reported to be expressed both 
by tumor and stromal cells. Interestingly, high stromal expression of VCAN, an anti-adhesive 
ECM protein-encoding gene (see 2.2.6), has been associated with shorter disease-free 
survival in several cancers, including prostate (Ricciardelli et al., 1998), breast (Ricciardelli 
et al., 2002), and endometrial cancer (Kodama et al., 2007). In turn, TIMP3 (Airola et al., 
1999) and CTHRC1 (Tang et al., 2006) expression have been found to be increased in 
invasive melanomas. Further, high CTHRC1 levels have been associated with poor prognosis 
in hepatocellular (Chen et al., 2013), breast (Kim et al., 2013), and colorectal cancer (Tan et 
al., 2013). 
To further search for genes potentially involved in melanoma metastasis, we analyzed the 
gene expression profiles of thick primary melanomas (Breslow’s thickness >2mm; n=7) and 
melanoma lymph node macrometastases (n=13) with Affymetrix HG-U133 set arrays. SAM 
resulted in 405 probesets representing 350 genes upregulated (≥1.5-fold) and 525 probesets 
representing 419 genes down-regulated (≥1.5-fold) in the macrometastases. The list of 
topmost significantly upregulated genes (Table 10; ≥2-fold presented) was filtered to remove 
“background” (B-cell-specific genes) resulting from comparing lymph node to skin tissue, 
although all samples were mostly comprised of melanoma cells. When we compared our up-
regulated genes with earlier studies that have done a similar comparison, we found few 
common genes, including transferrin receptor TFRC, SPP1, VEGFA, and NELL1 (Mauerer et 
al., 2011), as well as CKS2, SPP1, and MAGE family of antigens (Jaeger et al., 2007). In the 
pathway analysis, we found especially cell division (GO:0051301, p=4.6e-06) and cell cycle 
(KEGG:04110, p=0.000152) as well as the molecular function category term cyclin-
dependent protein serine/threonine kinase regulator activity (GO:0016538, p=0.00037) to be 
significantly associated with metastasis, suggesting that the melanoma metastases may be in a 
more proliferative state than the thick primary tumors. Single interesting up-regulated genes 
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also included CTSL1, SPP1, CXCR4, and ABCB5. We found the expression of CTSL1, SPP1, 
and CXCR4 to be up-regulated already in the progression of primary melanomas and now 
further in the metastases. In turn, ABCB5, a suggested melanoma stem-cell marker gene 
(Schatton et al., 2008), was not up-regulated in earlier steps of melanoma development and 
progression, but may here indicate a potential enrichment of stem-cell-like melanoma cells. 
8.4 Melanoma lymph node micrometastasis 
Melanoma metastases are usually found first in the SLNs draining the primary melanoma 
site, and the SLN status is considered to be the best independent indicator of patient 
prognosis. However, the mechanisms of the lymphatic metastatic process are still poorly 
understood, and the SLN analysis methods and markers currently in use lack in sensitivity 
and specificity (see 1.3.1). In order to molecularly characterize the metastatic cells and to find 
the best marker genes for the early detection of melanoma lymph node micrometastases, we 
compared the gene expression profiles of normal (n=12) and micrometastatic (n=12) lymph 
nodes analyzed with the HG-U133 set microarrays. SAM resulted in 25 probesets 
representing 22 annotated genes significantly over-expressed (≥4-fold) and 6 probesets 
representing 4 annotated genes under-expressed (≥4-fold) in the micrometastases (I: Table 1). 
Four-fold difference in the mean expression values between the groups was chosen to provide 
at least two PCR cycles to separate the metastases from normal tissue. Among the topmost 
over-expressed genes were   genes encoding antigens recognized by T cells (MLANA, 
PRAME, and MAGEA3), and genes encoding proteins involved in melanin biosynthesis 
(SILV, TYR, DCT, and TYRP1) or in signal transduction/cell proliferation (S100B, MIA, 
ERBB3, MET, and S100A1). The up-regulated gene SILV has been renamed as PMEL, 
DKFZP564K1964 has been annotated as TMEM98, the one unknown up-regulated transcript 
has been annotated as LHFPL3 antisense RNA1, and LOC284801 has been annotated as 
RNA45S5. As the use of the strict 4-fold cutoff may miss potential marker genes, we also 
checked the genes up-regulated 2- to 4-fold in the micrometastases (I: Supplementary Table 
4). Importantly, the best potential marker genes identified in our study were further up-
regulated in the macrometastases (I: Tables 1 and 2). The top marker genes (MLANA, PMEL, 
and TYR) in our study have been individually tested as potential RT-PCR markers in small 
biopsy specimens (Scoggins et al., 2006). Our approach was to develop more specific and 
gradable assays of MLANA, TYR, MIA, and ERBB3, as well as of new malignancy-specific 
markers. 
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Table 10. The topmost significantly over-expressed (≥2-fold) genes* in lymph node macrometastases 
compared to thick (>2 mm) primary melanomas by Significance Analysis of Microarrays (SAM). 
 
  Mean ± Stdev 
 Metastases 
vs primary 
melanomas 
Gene Gene description Probeset ID 
Primary 
melanomas 
(n=7) 
Macro-
metastases 
(n=13) 
 Fold 
SAM 
score
** 
HG-U133 A-array       
CKS2 CDC28 protein kinase regulatory subunit 2 204170_s_at 184 ± 117 660 ± 352  3.6 3.090 
SMC4 Structural maintenance of chromosomes 4 201664_at 132 ± 55 283 ± 104  2.1 2.600 
SRSF7 Serine/arginine-rich splicing factor 7 201129_at 106 ± 35 272 ± 126  2.6 2.558 
CCNB1 Cyclin B1 214710_s_at 111 ± 30 240 ± 99  2.2 2.366 
TOP2A Topoisomerase (DNA) II alpha 201292_at 128 ± 67 292 ± 131  2.3 2.360 
ACSL3 Acyl-CoA synthetase long-chain family member 3 201661_s_at 145 ± 92 424 ± 271  2.9 2.271 
TFRC Transferrin receptor (p90, CD71) 208691_at 578 ± 228 1283 ± 782  2.2 2.194 
RAB20 RAB20, member RAS oncogene family 219622_at 286 ± 93 587 ± 317  2.1 2.155 
CTSL1 Cathepsin L1 202087_s_at 531 ± 147 1483 ± 1133  2.8 2.111 
HMGB2 High mobility group box 2 208808_s_at 174 ± 47 381 ± 216  2.2 2.076 
RRM2 Ribonucleotide reductase M2 209773_s_at 277 ± 211 603 ± 364  2.2 1.954 
ARMCX2 Armadillo repeat containing, X-linked 2 203404_at 99 ± 41 203 ± 95  2.0 1.924 
SPP1 Secreted phosphoprotein 1 209875_s_at 967 ± 1091 1964 ± 1080  2.0 1.903 
CXCR4 Chemokine (C-X-C motif) receptor 4 217028_at 184 ± 117 660 ± 352  2.6 1.861 
LXN Latexin 218729_at 106 ± 35 272 ± 126  2.0 1.730 
NANS N-acetylneuraminic acid synthase 218189_s_at 111 ± 30 240 ± 99  2.8 1.722 
MRPS2 Mitochondrial ribosomal protein S2 218001_at 128 ± 67 292 ± 131  2.2 1.681 
SFRP4 Secreted frizzled-related protein 4 204051_s_at 110 ± 46  313 ± 287  2.8 1.609 
AURKA Aurora kinase A 208079_s_at 100 ± 35 237 ±182  2.4 1.600 
PHACTR1 Phosphatase and actin regulator 1 213638_at 166 ±106  349 ± 261  2.1 1.529 
ISG20 Interferon stimulated exonuclease gene 204698_at 173 ± 68 631 ± 744  3.6 1.520 
MAGEA12 Melanoma antigen family A, 12 210467_x_at 197 ± 203 512 ± 491  2.6 1.490 
CENPF Centromere protein F 207828_s_at 221 ± 99 493 ± 438  2.2 1.464 
        
HG-U133 B-array       
H19/ 
MIR675 
H19, imprinted maternally expressed 
transcript / microRNA 675 224646_x_at 130 ± 85 399 ± 209  3.1 2.412 
LHFPL3-
AS1 LHFPL3 antisense RNA 1 240366_at 153 ± 130 656 ± 533  4.3 2.141 
TBC1D7 TBC1 domain family, member 7 223461_at 349 ± 248 803 ± 529  2.3 1.881 
ABCB5 ATP-binding cassette, sub-family B (MDR/TAP), member 5 243167_at 60 ± 14 247 ± 249  4.1 1.512 
SLC16A6 Solute carrier family 16, member 6 230748_at 161 ± 186 615 ± 756  3.8 1.413 
MEGF10 multiple EGF-like-domains 10 232523_at 29 ± 14 137 ± 148  4.7 1.268 
BANCR BRAF-activated non-protein coding RNA 239239_at 106 ± 22 286 ± 299  2.7 1.260 
LAMA1 Laminin, alpha 1 227048_at 90 ± 51 225 ± 264  2.5 1.035 
FAM69B Family with sequence similarity 69, member B 229002_at 125 ± 29 273 ± 317  2.2 0.987 
Immune cell-related genes (background) have been filtered off. 
*Only annotated genes and the first probe set for each gene are shown. 
** FDR q-value was <0.001 for all genes. 
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As the occurrence of benign nevus cells in the lymph nodes may produce false-positive 
results when melanocyte-lineage-specific genes are used as markers, we checked the 
expression of the potential marker genes in benign nevi and primary melanomas to find 
melanoma-specific markers (I: Supplementary Table 3). As also mentioned earlier, PRAME 
and SPP1 were found to be highly up-regulated in the primary melanomas (see 8.1), thus 
presenting as promising markers for discriminating melanoma cells from nevus cells in the 
SLNs. We chose PRAME to be tested as a RT-PCR marker and SPP1 as an IHC marker 
(because of somewhat higher background expression in normal lymph nodes). Also, of the 
genes up-regulated 2- to 4-fold in the micrometastases, especially CTHRC1 and FN1 were 
found to be interesting malignancy-related candidate genes for metastasis markers (IV: 
Supplemental Table S1). 
In order to dissect whether there are genes which are specifically up-regulated in the early 
metastatic melanoma cells compared to the melanoma cells in the primary tumors, we 
normalized the expression values with the expression levels of genes we have found to show 
rather constant expression through-out melanoma development and progression: MLANA, 
SOX10, and PLP1. Most genes were found to show comparable expression levels in the 
micrometastases and the primary tumors (data not shown), suggesting that micrometastasis to 
SLNs is a fairly non-selective process, i.e. not associated with changes in gene expression 
profiles or metastasis of a specific subpopulation of cells. 
8.5 Outgrowth of melanoma metastases 
Although the growth of micrometastases into macrometastases is the rate-limiting step of the 
metastatic process (see 3.2), the underlying molecular mechanisms are largely unknown. To 
study the molecular changes behind the outgrowth of melanoma metastases, we compared the 
gene expression profiles of melanoma lymph node micrometastases (<2.5 mm diameter; n=9) 
and macrometastases (>2.5 mm diameter; n=13) analyzed with the HG-U133 set microarrays. 
SAM resulted in 1461 probesets representing 1139 genes significantly up-regulated (≥1.5-
fold) (II: Table 1 and Supplemental Tables S2 and S3: ≥4-fold changes; Supplemental Tables 
S6 and S7: two- to four-fold changes) and 1092 probesets representing 791 genes 
significantly down-regulated (≥1.5-fold) (II: Supplemental Table S4 and S5; ≥4-fold 
changes) in the macrometastases. Inspection of the results revealed no common up-regulation 
of any single growth factor or cytokine. This may be due to the heterogeneity of melanomas, 
as some growth factors, including GDF15 and IL-8, were up-regulated in individual 
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metastases (data not shown). Metastatic melanoma cells may also have developed growth 
factor-independency, as melanoma cells derived from metastases have been found to grow 
without any polypeptide growth factors at least in vitro (Rodeck et al., 1987). Also, over-
expression of some growth factor or cytokine-like proteins, especially SPP1, which showed 
21.5-fold over-expression in the macrometastases, may play an important role in the 
outgrowth of melanoma metastases and provide interesting therapeutic targets. Pathway 
analysis of all up-regulated genes revealed especially genes involved in oxidative 
phosphorylation [KEGG:00190, p<3e-06; GO biological process terms: generation of 
precursor metabolites and energy (GO:0006091, p=2.9e-13), respiratory electron transport 
chain (GO:0022904, p=2.1e-10), oxidation-reduction process GO:0055114, p=7.8e-10)] to be 
up-regulated in the macrometastases, in concordance with a recent study suggesting that 
oxidative phosphorylation may fuel the growth of melanoma metastases in addition to 
glycolysis (Ho et al., 2012). In turn, a pathway analysis of the genes up-regulated ≥4-fold 
suggested that changes in contacts between the cell and the ECM are common events during 
the growth of melanoma metastases, as the most significantly associated KEGG pathways 
were ECM-receptor interaction (04512, p=6e-06) and focal adhesion (04510, p=0.000219). 
Most importantly, however, another pathway analysis tool Gene Set Enrichment Anlaysis 
(GSEA) indicated that TGFβ-regulated genes may play an important role in the outgrowth of 
melanoma metastases. Indeed, we found several TGFβ-regulated genes encoding ECM 
proteins, including FN1, COL-I, POSTN, and VCAN, to be among the most highly and 
consistently up-regulated genes in the macrometastases (II: Table 1). By hierarchical gene 
clustering, we further found the expression of these genes to correlate with each other in the 
melanoma micro- and macrometastases as well as in breast cancer lymph node metastases (II: 
Figure 2 and Supplemental Tables S9-S12), suggesting coordinated expression. 
To further study the specific changes in gene expression during the growth of melanoma 
metastases, we performed an analysis of three paired SLN metastases and lymph node 
macrometastases (i.e. obtained from the same patients). Pairwise SAM resulted in 1499 
probesets representing 1235 genes up-regulated (Table 11; topmost genes with ≥3-fold 
changes) and 762 probesets representing 575 genes down-regulated in the metastases. Here, 
we found an up-regulation of MIF (SAM score 1.680, fold 3.2), a cytokine reported to be 
over-expressed by melanoma cells and to enhance proliferation and migration of melanoma 
cells (Shimizu et al., 1999). As a key pro-inflammatory protein, MIF may also play an 
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important role in the tumor microenvironment (reviewed in Conroy et al., 2010). It has also 
been found to promote the growth of fibroblasts (Mitchell et al., 1999) and to play a role in 
tumor-induced angiogenesis (Shimizu et al., 1999), providing an interesting target for 
therapy. However, more significantly over-expressed in the macrometastases were again 
FN1, COL-I, POSTN, and VCAN together with other TGFβ-regulated genes, such as TIMP1 
and ITGB5 (Table 11). Further, we found many proteases among the up-regulated genes, 
including the cysteine cathepsins B, L1, and K, serine proteases PLAT and PLAU, as well as 
MMP14, strengthening the idea that genes encoding ECM proteins and ECM modifying 
enzymes play an important role in the outgrowth of melanoma metastases. Of note, CTHRC1, 
which we found to be up-regulated in the metastatic primary melanomas, was also highly up-
regulated in the growth of paired lymph node metastases. In subsequent studies, we 
concentrated on investigating the role of these ECM proteins in melanoma. 
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Table 11. The topmost significantly over-expressed (≥3-fold) genes* in melanoma lymph node 
macrometastases compared to paired SLN micrometastases by SAM. 
   Signal  SAM 
score
** 
   Micrometastases Macrometastases  
Gene Gene description Probe set ID I II III I II III Fold 
HG-U133 A-array          
FN1 Fibronectin 1 212464_s_at 500 3793 278 4956 7051 4136 8.9 7.319 
MT2A Metallothionein 2A 212185_x_at 1619 2093 948 5927 4567 3961 3.3 4.503 
TIMP1 TIMP metallopeptidase inhibitor 1 201666_at 1510 3111 859 4255 8365 3736 3.3 3.640 
COL3A1 Collagen, type III, alpha 1 201852_x_at 1387 1419 400 2755 3409 3240 4.2 3.401 
SRPX Sushi-repeat containing protein, X-linked 204955_at 201 845 179 952 1655 1223 4.5 3.215 
MT1X Metallothionein 1X 208581_x_at 788 989 724 3268 2459 2001 3.1 3.145 
CTSB Cathepsin B 200838_at 1789 996 1457 3946 4817 3151 3.1 3.093 
COL1A2 Collagen, type I, alpha 2 202403_s_at 1549 2247 929 2991 5247 5016 3.2 2.997 
WARS Tryptophanyl-tRNA synthetase 200629_at 630 614 459 3036 3240 1489 4.4 2.970 
GPNMB Glycoprotein (transmembrane) nmb 201141_at 1166 2343 584 3683 3549 4004 3.8 2.889 
CD59 CD59 molecule 200983_x_at 1489 2916 866 6615 4775 3730 3.5 2.862 
POSTN Periostin, osteoblast specific factor 210809_s_at 126 2155 40 1800 3171 2510 26.4 2.858 
COL1A2 Collagen, type I, alpha 2 202404_s_at 430 784 128 1317 2553 2512 8.6 2.729 
LGALS1 Lectin, galactoside-binding, soluble, 1 201105_at 1003 2780 1047 4368 3995 5411 3.7 2.685 
LGALS3BP Lectin, galactoside-binding, soluble, 3 binding protein 200923_at 370 1002 257 1150 2204 2048 4.4 2.654 
IER3 Immediate early response 3 201631_s_at 367 366 215 1788 1004 1483 4.8 2.637 
VCAN Versican 221731_x_at 88 406 50 573 1504 1009 10.2 2.313 
ANXA2 Annexin A2 213503_x_at 1372 3146 2006 7100 4326 5383 3.1 2.295 
MIA 
Melanoma inhibitory 
activity 
206560_s_at 
 399 1489 239 1865 3062 675 3.2 2.131 
ITGB5 Integrin, beta 5 201125_s_at 215 419 218 983 870 1279 4.2 2.128 
COL1A1 Collagen, type I, alpha 1 202310_s_at 1205 1006 281 2138 3491 5116 7.8 2.092 
SPP1 Secreted phosphoprotein 1 209875_s_at 209 4139 85 2321 4586 1743 10.9 2.073 
PMEL Premelanosome protein 209848_s_at 738 1399 865 7666 1706 8753 7.2 1.966 
CALU Calumenin 200757_s_at 416 612 212 1598 945 1241 3.7 1.918 
LAPTM4B Lysosomal protein transmembrane 4 beta 214039_s_at 364 1045 360 1970 1358 2257 4.3 1.905 
CTSL1 Cathepsin L1 202087_s_at 585 599 604 2673 902 1786 3.0 1.711 
          
HG-U133 B -array          
CTHRC1 Collagen triple helix repeat containing 1 225681_at 204 443 113 1749 1267 2009 9.7 2.877 
FAM210B Family with sequence similarity 210, member B 224690_at 476 939 245 2091 1548 1811 4.5 2.497 
BRI3 Brain protein I3 223376_s_at 661 901 373 2155 1197 1905 3.2 1.896 
CNIH4 Cornichon homolog 4 223993_s_at 230 475 183 1173 744 952 4.0 1.736 
LATS2 Large tumor suppressor kinase 2 227013_at 203 258 118 643 563 695 3.7 1.714 
*Only annotated genes and the first probe set for each gene are shown. 
** FDR q-value was <0.005 for all genes. 
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9. FUNCTIONAL CHARACTERIZATION (II-IV) 
9.1 Periostin, fibronectin, and collagen-I in the outgrowth of melanoma 
metastases (II) 
9.1.1 Periostin expression in fibroblasts, melanoma cells, and metastatic melanoma 
tissues 
POSTN is a secreted matricellular protein with four integrin-interacting FAS domains and an 
alternatively spliced C-terminal domain (see 2.2.5). We first confirmed the highly up-
regulated expression of POSTN in melanoma lymph node macrometastases compared to 
micrometastases found in the microarray analyses (see 8.5) by a qRT-PCR assay detecting all 
known POSTN splice-variants (II: Figure 1A). Further, we studied if some specific isoforms 
of POSTN are up-regulated in the macrometastases. By a semiquantitative RT-PCR assay 
encompassing the C-terminal region of POSTN, we found a total of five splice-variants in 
addition to the full-length POSTN to be expressed in the macrometastatic tissues, with larger 
isoforms showing relatively higher expression (II: Figure 1B and C). Primary embryonic and 
adult skin fibroblasts were found to express several splice-variants excluding the full-length 
POSTN. Although fibroblasts appear to be the main producers of POSTN, some melanoma 
cells isolated from metastases showed similar expression pattern to fibroblasts, suggesting 
that these cells have acquired the ability to express elevated levels of several POSTN 
isoforms and may be thus less dependent on fibroblasts (II: Figure 1B). 
9.1.2 Periostin, fibronectin, collagen-I, and versican co-localize in fibrillar structures 
surrounding melanoma cells in metastatic tissues 
As we found POSTN to be coordinately expressed with FN1, COL-I, and VCAN (all TGFβ-
regulated genes) in melanoma as well as breast cancer lymph node metastases (see 8.5), we 
studied their localization in the metastatic tissues by immunohistochemistry and confocal 
microscopy. In melanoma macrometastases from lymph nodes, lung, and liver, POSTN, FN1, 
PCOL-I, and VCAN were found to co-localize in extracellular fibrous strand and ring 
structures surrounding individual melanoma cells or cell nests (II: Figures 3, 6, and 7, 
Supplemental Figure S4), especially at the tumor-stroma interface (II: Figure 4D and H, 
Supplemental Figure S3). Similar structures were found in breast cancer metastases, speaking 
for the generality of the finding. Micrometastases, in turn, were mostly devoid of these 
structures, showing only faint staining of FN1 and absent or faint staining of the other 
proteins. Only few micrometastases expressed moderate levels of POSTN and FN1 (II: 
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Figure 4A-C, E-G). Interestingly, we also found TGFβ/Smad2-signaling to be activated in all 
melanoma lymph node macrometastases both in the melanoma cells and fibroblasts, 
especially at the tumor-stroma interface (II: Figure 4, Supplemental Figure S1, Supplemental 
Table S8). In micrometastases, the phospho-Smad2 staining seemed to correlate best with the 
intensity of POSTN. Whether the staining patterns of these proteins in micrometastases hold 
any prognostic value or could differentiate actively growing micrometastases from dormant 
ones, remains an important question to study. Interestingly, an important regulative role for 
these proteins in the growth of micrometastases is supported by a recent study where the 
outgrowth of dormant disseminated breast cancer cells was found to be promoted by TGFβ 
and POSTN expressed by neovascular endothelium (Ghajar et al., 2013). Also, FN1, VCAN, 
and TNC were found to be enriched in these micrometastatic niches, but their significance in 
the growth of the metastases was not assessed in that study. 
We further explored the spatial organization of COL-I, FN1, and POSTN in the fibrillar 
structures by confocal microscopy. COL-I and FN1 fibers seemed to form together the core 
structure around which POSTN was deposited (II: Figure 7, Supplemental Movies S1 and 
S2). Our in vitro surface plasmon resonance experiments indicated that these proteins can 
directly interact with each other and also bind themselves (II: Supplemental Figure S6), 
which is likely to be important for the assembly of these structures. Of note, a recombinant 
POSTN fragment lacking the alternatively spliced C-terminal domain failed to bind COL-I or 
FN1. The spatial organization of the fibrillar structures seen in the confocal images suggested 
that at least the core proteins, FN1 and COL-I, are copolymerized. Indeed, the polymerization 
of COL-I has been found to be dependent on FN1 and also the FN1 polymerization is 
enhanced by COL-I (see 2.2.2). Interestingly, also POSTN has been found to regulate COL-I 
fibrillogenesis in vivo (Norris et al., 2007) and, recently, to protect COL-I matrices from 
digestion by collagenases in vitro (Egbert et al., 2014). In another recent study, POSTN was 
found to have an effect, in addition to COL-I, on the distribution of FN1 and TNC in vivo 
(Tabata et al., 2014). We have previously found TNC to co-localize with FN1 and COL-I in 
fibrillar structures in invasive melanomas (Kääriäinen et al., 2006). Here, TNC was found to 
co-localize with FN1 and POSTN in similar fibrillar networks in the melanoma metastases 
(II: Supplemental Figure S5). We further found POSTN and FN1 to be specifically up-
regulated in the immature tumor blood vessels (II: Figure 5J-N), suggesting that these two 
proteins may play a role in angiogenesis during the outgrowth of melanoma metastases. Both 
FN1 and POSTN have been found to promote vascular cell migration and tubulogenesis 
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(Khan et al., 2005; Lindner et al., 2005; Siriwardena et al., 2006; Zhou et al., 2008). In 
addition, FN1 may promote angiogenesis by inducing VEGF-A expression (Khan et al., 
2005) and POSTN has been found to enhance the expression of VEGF receptor KDR in 
endothelial cells (Shao et al., 2004). Interestingly, POSTN may also promote metastasis 
through increased lymphangiogenesis. It has been found to enhance VEGF-C expression in 
cancer cells and directly to promote lymphatic endothelial cell tubulogenesis through Src and 
Akt activation (Kudo et al., 2012). 
 
9.1.3 Full-length periostin has an anti-adhesive effect on tumor and stromal cells 
COL-I and FN1 are both well-known cell adhesion molecules regulating several cellular 
processes including cell survival, proliferation, and migration (see 2.2.1 and 2.2.2).  POSTN 
is also thought to function as an adhesion molecule as it contains four FAS domains, which 
may interact with integrin receptors. However, one study has reported full-length POSTN to 
be anti-adhesive for cardiac fibroblasts (Katsuragi et al., 2004). We tested the effect of 
POSTN as well as other ECM proteins, FN1, COL-I, and TNC, on adhesion of melanoma 
cells, fibroblasts, and endothelial cells. Surprisingly, we found the coatings of recombinant 
full-length POSTN to have an anti-adhesive effect on all the cell types tested (II: Figure 8A 
and B). The POSTN fragment, in contrast, supported the adhesion (although less efficiently 
than FN1 or COL-I) of some cell types, including fibroblasts, endothelial cells, and WM793 
melanoma cells (II: Figure 8A and B), suggesting that the POSTN fragment may have a 
conformation different to that of the full-length POSTN and have its FAS domains more 
accessible. As a further support of the anti-adhesive effect of POSTN, the knockdown of 
endogenous POSTN expression by shRNAs in the metastatic melanoma cell line WM239 (for 
the level of knockdown see II: Supplemental Figure S7) as well as in fibroblasts and 
endothelial cells was found to promote cell adhesion, whereas FN1 knockdown inhibited cell 
adhesion (shown for WM239 cells, II: Figure 8C). Interestingly, when the cells were plated 
on surfaces coated with full-length POSTN mixed 1:1 with FN1 (or COL-I, data not shown), 
POSTN was found not to inhibit the adhesion of fibroblasts or melanoma cells but to induce a 
more elongated, spindle-like phenotype (II: Supplemental Figure S8), suggesting that the full-
length POSTN modulated the adhesive functions of FN1 and COL-I. 
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9.1.4 Full-length periostin combined with fibronectin or collagen-I increases migration 
of melanoma cells, fibroblasts, and endothelial cells 
The migratory spindle-like phenotype induced by full-length POSTN prompted us to test the 
effect of POSTN on cell migration. WM793 melanoma cells, fibroblasts, and endothelial 
cells were all found to show increased migration through transwell cell culture inserts coated 
with POSTN and cFN, or POSTN and COL-I (1:1) compared to inserts coated with cFN and 
COL-I alone, respectively (results are shown for WM793 and endothelial cells, II: Figure 9). 
The POSTN fragment, in turn, showed no enhancement of migration in a similar setting (II: 
Figure 9A), suggesting that the anti-adhesive property of the full-length POSTN and the 
ability to bind COL-I and FN1 are important for the pro-migratory effect. By binding to 
COL-I and FN1, POSTN may weaken cell adhesion to these proteins, thus allowing 
sequential attachment and detachment required for efficient migration (see 3.1.2). As a 
further support of the pro-migratory effect of POSTN, knockdown of POSTN by shRNAs 
was found to inhibit the migration of fibroblasts through cFN-coated filters by 30% 
(p=0.049). Similar results were obtained with WM239 melanoma cells. 
9.1.5 Fibronectin is required for cell growth 
When we analyzed the effect of POSTN and FN1 on cell proliferation in the POSTN- and 
FN1-knockdown cells, FN1, but not POSTN, was found to be needed for the growth of 
melanoma cells, fibroblasts, and endothelial cells in the presence of serum growth factors 
(shown for fibroblasts, II: Figure 10A). Further, the co-culture-promoted growth of WM793 
melanoma cells and fibroblasts in serum-free medium was inhibited by an anti-FN1 antibody 
L8 that prevents the polymerization of FN1 (II: Figure 10B). Although it has been suggested 
that soluble FN1 in serum may be incorporated in the same structures as endogenous FN1 
(Hayman and Ruoslahti, 1979), our results indicate that specifically the polymerization of 
endogenous FN1 is essential for the growth of cells. 
Taken together, these data suggest that POSTN and FN1 provide attractive potential targets 
for novel therapies against disseminated melanomas as well as breast cancer by affecting 
tumor and stromal cell migration, growth, and angiogenesis - the key processes of metastasis. 
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9.2 Collagen triple helix repeat containing 1 in melanoma development and 
progression (IV) 
9.2.1 CTHRC1 is expressed by melanoma cells and stromal fibroblasts and endothelial 
cells 
CTHRC1, a highly conserved glycosylated protein with an amino-terminal signal sequence 
for secretion and a short collagen triple helical domain, has been found to be over-expressed 
in several cancers, including breast, colon, ovary, liver, and lung cancers, as well as in 
melanoma (se 2.2.7). Our goal was to define the relevance of CTHRC1 in melanoma 
development and progression. We first confirmed the CTHRC1 over-expression in primary 
melanomas compared to benign nevi by qRT-PCR analysis in two sample sets, and found the 
up-regulation of CTHRC1 mRNA in the melanomas to be 4.7- to 11.8-fold (p= 0.000907 and 
0.0147, respectively; IV: Figure 1A). Next, we analyzed the mRNA and protein expression of 
CTHRC1 in different primary cells and cell lines by qRT-PCR and western blotting, as well 
as the protein expression in primary melanoma tissues by IHC, to find out which cell types 
may be responsible for CTHRC1 expression in melanoma and to see the localization of the 
protein in the tissues. Previous studies have mainly reported CTHRC1 to be expressed by 
melanoma cells. However, we found also stromal cells to express CTHRC1. In vitro, primary 
embryonic and adult skin fibroblasts were found to express higher CTHRC1 levels than 
microvascular endothelial cells as well as melanoma cells isolated from primary tumors and 
metastases, which showed moderate CTHRC1 expression (IV: Figure 1B). Some melanoma 
cell lines, including the VGP WM115 and the metastatic MM170, SKMEL-28, and WM239 
cell lines, were found to express very high levels of CTHRC1 mRNA and protein (IV: 
Figures 1B, and 2A and B). In normal melanocytes and benign nevus cells, in turn, CTHRC1 
expression was virtually absent (IV: Figure 1B). 
In tissue specimens, benign nevus cells showed faint or moderate immunostaining of the 
CTHRC1 protein (Figure 8A; IV: Figure 3A). In turn, primary and metastastic melanomas 
showed moderate to strong CTHRC1 staining, with stronger staining usually seen at the 
tumor-stroma border (Figure 8B and C; IV: Figure 3 and Supplemental Figure S5), 
suggesting that the contacts between melanoma and stromal cells may play a role in inducing 
CTHRC1 expression in the melanoma tissues. Strong CTHRC1 expression was also seen in 
the fibroblasts surrounding melanoma cell nests and in endothelial cells in both developing 
and more mature blood vessels (Figure 8B and C; IV: Figure 3 and Supplemental Figure S5). 
As CTHRC1 is a secreted protein, it could be hypothesized that it may also function as a 
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paracrine factor in the tumor microenvironment, regardless of the cell type producing it. This 
could also explain the observed situation in some tumors, where the most intense staining 
was seen in different cell types in different areas of the tumor (IV: Supplemental Figure S5). 
In any case, it appeared that the up-regulation of CTHRC1 seen at the mRNA level is largely 
due to increased density of blood vessels and activation of fibroblasts. Interestingly, 
CTHRC1 was originally found to be induced in adventitial fibroblasts and neointimal smooth 
muscle cells after vascular injury, and to promote the migration of these cells in vitro (Pyagay 
et al., 2005). Fitting with this, we found by hierarchical gene clustering (IV: Supplemental 
Figure S4), CTHRC1 mRNA expression in primary melanomas to correlate with genes 
involved in blood vessel development (GO:0001568, p=9.1e-06) and locomotion 
(GO:0040011, p=9.1e-06). One of the coordinately expressed genes was FN1, which we 
further found to co-localize with CTHRC1 in the fibrotic structures surrounding melanoma 
cells and in blood vessels (IV: Figure 3M-O). 
Importantly, we found high mRNA expression of both CTHRC1 and FN1 in the primary 
melanomas to associate with poor survival (IV: Supplemental Figure S1), suggesting these 
genes could also serve as prognostic factors, although their significance needs to be further 
tested in a larger patient group. 
 
Figure 8. Immunostaining of CTHRC1 in a benign nevus (A), a primary melanoma (B), and a 
melanoma lymph node macrometastasis (C). Examples of fibroblasts are marked with arrows and 
blood vessels with asterisks. Original magnification 200x. 
 
9.2.2 CTHRC1 is coordinately expressed with FN1, ITGB3, and NFATC2 in melanoma 
cell lines 
To investigate in which processes CTHRC1 may function in melanoma cells, we searched for 
genes showing expression correlating with that of CTHRC1 in our own panel of primary cells 
and cell lines as well as a in a set of 34 melanoma cell lines obtained from a databank (E-
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GEOD-7152). We found FN1, GPR126, NFATC2, and ITGB3 to show positive correlation 
with CTHRC1 expression in both datasets (IV: Supplemental Table S6). We confirmed the 
similar expression pattern of FN1, ITGB3, and NFATC2 in our panel of eight melanoma cell 
lines by RT-PCR (IV: Figure 2C). FN1 and ITGB3 were expressed in a similar fashion to 
CTHRC1 also at the protein level (IV: Figure 2A and B). This coordinate expression may at 
least partly be explained by a concerted regulation by TGFβ as CTHRC1, FN1, ITGB3, and 
NFATC2 have all been suggested to be TGFβ target genes (Fernandez-Zapico and 
Ellenrieder, 2010; Ignotz et al., 1987; Platten et al., 2000; Pyagay et al., 2005). In 
concordance with CTHRC1 being a TGFβ-regulated gene, CTHRC1 protein levels were 
reduced in a dose-dependent manner after treatment with increasing concentrations of a 
specific TGFβ-receptor I/ALK-5 inhibitor SB505124 (IV: Figure 5F and G). Interestingly, 
the expression of CTHRC1, FN1, and ITGB3 may further be regulated by NFATC2 (a 
calcineurin-dependent transcription factor) as we found their protein expression to decrease 
after treatment with cyclosporine A, an inhibitor of calcineurin/NFAT activity (IV: Figure 5A 
and B). Further, a down-regulation of NFATC2 expression by specific siRNAs resulted in a 
reduction of CTHRC1 protein levels (IV: Figure 5C). Also, when investigating other 
regulatory relationships between these proteins, we found inhibition of integrin αvβ3 activity 
with neutralizing antibodies to reduce CTHRC1 protein expression (IV: Figure 5H). These 
potential regulators of CTHRC1 expression have been implicated in many malignant 
processes, including tumor cell migration and invasion as well as angiogenesis (reviewed in 
Guo and Giancotti, 2004; Mancini and Toker, 2009). In melanoma, integrin β3 has been 
suggested to play an important role especially in the conversion from radial to vertical growth 
phase (Hsu et al., 1998), and NFATC2 to promote the survival of melanoma cells (Perotti et 
al., 2012). 
9.2.3 CTHRC1 is required for migration and invasion of melanoma cells 
As the genes correlating with CTHRC1 are associated in cell adhesion and migration, and 
also CTHRC1 has been suggested to be a pro-migratory protein, we tested the effect of 
CTHRC1 on the adhesion and migration of melanoma cells. Surfaces coated with a 
recombinant full-length CTHRC1 protein did not, however, support the adhesion of WM793, 
WM239, or MM170 melanoma cells, or adult skin fibroblasts (IV: Figure 4A). Also, WM239 
cells with their endogenous CTHRC1 expression knocked down with specific shRNAs (for 
the level of knockdown see IV: Supplemental Figure S7A-C) showed no difference to control 
shRNA-expressing cells in their cell adhesion properties when plated onto uncoated surfaces 
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or surfaces coated with ECM proteins FN1, COL-I, or laminin (data not shown). Yet, when 
we investigated the effect of endogenous CTHRC1 on cell migration through transwell cell 
culture inserts, CTHRC1-knockdown cells showed a significant decrease (4.4-fold at 22 
hours, p=0.002; 4.3-fold at 42 hours, p<0.0001) in their ability to migrate compared to the 
control shRNA cells (IV: Figure 4B). Most importantly, when we investigated the effect of 
CTHRC1 on cell migration and invasion in 3D COL-I gel and Matrigel assays mimicking 
more closely the situation in vivo, we found the knockdown of CTHRC1 in WM239, 
SKMEL-28, and MM170 melanoma cell lines to markedly reduce the invasive growth of 
these cells (IV: Figure 4C-E, Supplemental Figure S8A).     
9.2.4 Possible effectors in CTHRC1-promoted migration and invasion 
Although CTHRC1 has a clear effect on cell migration and invasion, the exact mechanisms 
of CTHRC1 function are still largely unknown. To unravel these mechanisms, we compared 
the gene expression profiles of wild-type as well as control and CTHRC1 shRNA-expressing 
WM239 melanoma cells. We found several potential effectors of CTHRC1, including 
WNT5A, which was down-regulated in the CTHRC1-knockdown cells (IV: Supplemental 
Table S7). CTHRC1 has been suggested to bind WNT5A and stabilize the Wnt-receptor 
interaction, and thus increase non-canonical Wnt signaling (Yamamoto et al., 2008). 
Interestingly, activation of Wnt signaling by CTHRC1 may result in a positive feedback loop, 
where the expression of both WNT5A and CTHRC1 is induced by downstream protein 
kinase C (Jonsson et al., 1998) and NFAT signaling (Saneyoshi et al., 2002), respectively, 
fitting with the observed down-regulation of WNT5A expression after the knockdown of 
CTHRC1. Other interesting molecules potentially functioning downstream of CTHRC1 were 
cofilin 1 (CFL1), a central regulator of actin dynamics in cell migration, as well as aldo-keto 
reductase family 1, member C3 (AKR1C3) and fatty acid binding protein 7 (FABP7), which 
have been linked to migration and invasion of tumor cells (De Rosa et al., 2012; Mita et al., 
2010; Wu et al., 2014), potentially through inhibiting PPARγ activation and expression (Mita 
et al., 2010; Penning et al., 2006). The importance and function of these genes in CTHRC1-
mediated cell migration and invasion remains an interesting subject of future research. 
Taken together, our data propose that CTHRC1 is a part of the pro-invasive and pro-
angiogenic transcription program induced by TGFβ and NFATC2, providing thus an 
interesting target for treating invasive and metastatic melanomas. 
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9.3 Cathepsins B and L1 in melanoma cell invasion (III) 
Cysteine cathepsins have been found to play important roles in many processes during tumor 
progression, including angiogenesis, cell proliferation, and invasion (see 3.1.3.3). In our 
microarray analyses, we found especially cathepsins B and L1 to be over-expressed in thick 
primary melanomas compared to benign nevi (III: Table 1). Their expression was also found 
to be up-regulated both in primary melanoma progression as well as in the outgrowth of 
melanoma metastases. High CTSB mRNA expression in the primary melanoma tumors was 
further found to be significantly associated with poor survival in the SAM survival analysis 
(data not shown) and in the Kaplan-Meyer survival analysis (III: Supplemental Figure S9), 
suggesting it to be a potential prognostic marker for melanoma patient outcome. 
9.3.1 Cathepsin B and L1 protein expression in benign nevi and primary melanomas 
To verify the microarray analysis results and to see the localization of CTSB and CTSL1 in 
tissues, we analyzed the protein expression of these proteases in benign nevi (n=13) and 
primary melanomas (n=60) by immunohistochemistry. The expression of CTSB and CTSL1 
was undetectable or low in benign nevus cells and in the surrounding fibroblasts (III: Figure 
6A and D). In primary melanomas, elevated levels of CTSB expression were found in 
melanoma cells, with some cells showing intense cytoplasmic and membrane staining (III: 
Figure 6B and C), especially at the tumor-stroma border (III: Supplemental Figure S14). Also 
CTSL1 was expressed by melanoma cells, but at a lower level than CTSB (III: Figure 6E and 
F). Interestingly, the stromal fibroblasts surrounding the melanoma cell nests were found to 
express high levels of CTSL1, the staining intensity of which was further increased with the 
melanoma cell invasion depth (III: Figure 6E and F). These results prompted us to study the 
effects of CTSB and CTSL1 in invasion of melanoma cells, especially in a 3D co-culture 
system with fibroblasts. 
9.3.2 Effects of cathepsin B/L inhibitors on the invasive growth of melanoma cells and 
fibroblasts 
We first tested the invasive growth capacity of early VGP WM793 melanoma cells alone or 
mixed in a 1:1 ratio with skin fibroblasts in 3D Matrigel and Matrigel/COL-I matrices, which 
mimic the in vivo environment. The WM793 cells alone showed some invasive growth 
potential but only during prolonged culture (III: Figure 1A and D, Supplemental Figure S1A 
and B), whereas the skin fibroblasts were unable to invade or even survive on their own in 3D 
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Matrigel (III: Figure 1B and E). However, when these cells were cultured together in 3D 
Matrigel, the melanoma cells were found to activate the fibroblasts, which assembled into 
direct contact with the melanoma cells, resulting in a dramatic increase of invasive growth of 
both cell types (III: Figure 1C and F). In addition to cell-cell contacts, fibroblasts appeared to 
be activated by soluble factors secreted by the melanoma cells, because their activation also 
occurred without direct contact to melanoma cells (III: Figure 1G-L) as well as on mere 
addition of conditioned growth medium from the melanoma cells (III: Supplemental Figure 
S2). Further, also the reciprocal activation of melanoma cells by the activated fibroblasts may 
be stimulated by soluble factors, as conditioned medium from embryonic fibroblasts was 
found to induce an EMT-like phenotype in the WM793 melanoma cells and increase their 
invasive activity (III: Supplemental Figure S3A). Interestingly, though, examination of the 
co-culture growth patterns suggested that the fibroblasts were almost always the leading cells 
in the cell invasion fronts (III: Figure 2C and D). Fitting with the idea of fibroblast leading 
the way for melanoma cells, fibroblasts have also been shown to lead the invasion of 
squamous carcinoma cells in a similar in vitro system (Gaggioli et al., 2007). 
As proteases have been found to play an important role in tumor cell invasion and we found 
CTSB and CSTL1 to be highly expressed by melanoma cells and fibroblasts, respectively, at 
the invasive fronts of melanoma primary tumors, we tested the effect of CTSB and CTSL 
inhibitors on the co-invasive growth of melanoma cells and fibroblasts. Interestingly, the 
activation of fibroblasts (III: Figure 5J and L, Supplemental Figure S13J and L), the 
interaction between WM793 cells and fibroblasts, and their co-invasive growth (III: Figure 
4F and G, Supplemental Figures S10F and G, and S11E and F) were significantly inhibited 
by cell membrane-permeable inhibitors for CTSB (CA-074 Me) and CTSL (Z-FF-FMK). 
However, the cell membrane-impermeable CTSB inhibitor (CA-074) showed no significant 
effect on the invasive growth of the cells (III: Figure 4E, Supplemental Figures S10E and 
S11D), suggesting that intracellular rather than secreted CTSB plays an essential role in 
invasion through 3D Matrigel, fitting with earlier results (Szpaderska and Frankfater, 2001). 
Interestingly, although MMPs are generally thought to play an important role in tumor cell 
invasion, a wide-spectrum MMP inhibitor (GM6001) had no significant effect on the invasive 
growth of the co-cultured cells (III: Supplemental Figures S10B and S11C), but was able, 
similarly to all above inhibitors, to significantly inhibit the low invasive capacity of WM793 
cells alone (III: Supplemental Figure S1). Importantly, similar results were obtained when the 
effects of all the above protease inhibitors were tested on the invasive growth of other 
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melanoma cell lines (WM115, SKMEL-28, SKMEL-103, and SKMEL-147) co-cultured with 
embryonic fibroblasts (data not shown). Taken together, these results suggest that CTSB and 
CTSL1 play critical roles in melanoma cell invasion and may serve as potential therapeutic 
targets for invasive melanomas. 
9.3.3 TGFβ-signaling in the invasive growth of melanoma cells and fibroblasts 
As TGFβ has been found to regulate the activation of fibroblasts (Kojima et al., 2010) and 
latent TGFβ is expressed constitutively by most melanoma cells, including WM793 cells 
(Rodeck et al., 1994), we studied the possibility that TGFβ secreted by melanoma cells could 
play a role in promoting the invasive growth of melanoma cells and fibroblasts by inducing 
the expression of CTSL1 in fibroblast (because in melanoma tissues, the fibroblasts at the 
invading front showed high CTSL1 expression). Indeed, both TGFβ and the conditioned 
medium from WM793 cells stimulated CTSL1 mRNA expression in skin fibroblasts (III: 
Supplemental Figure S15A). In turn, the conditioned medium from activated fibroblasts was 
found to stimulate CTSB protein expression in WM793 cells (III: Supplemental Figure 
S15B). In addition, inhibition of CTSB activity in WM793 cells with the cell membrane-
permeable inhibitor (Ca-074 Me) markedly reduced the secretion/production of the inactive 
large latent complex of TGFβ (III: Figure 7), which is known to be further activated by CTSB 
(Guo et al., 2002). Most importantly, in the functional co-culture assays, we found both the 
specific inhibitor of TGFβ receptor I/ALK5 and the pan-neutralizing TGFβ antibody to 
significantly inhibit the activation of fibroblasts and the subsequent invasive growth of 
melanoma cells and fibroblasts (III: Figure 8, Supplemental Figures S16 and S17). 
Collectively, these data suggest that TGFβ and cathepsins B and L1 play important roles in 
the invasive growth of melanoma cells, creating a positive feedback signaling loop where 
intracellular CTSB of melanoma cells first regulates the secretion and activation of TGFβ, 
which may function in an autocrine manner or stimulate (together with other growth factors) 
fibroblasts to produce cathepsin L1 and other molecules, which in turn reciprocally stimulate 
the production of CTSB in melanoma cells. CTSB and CTSL1 may promote the invasive 
growth of the cells by creating pathways for the invading cells by digesting ECM proteins 
and activating other proteases, as well as releasing and activating growth factors embedded in 
the ECM (see 3.1.3.3). 
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10.  MARKERS FOR MELANOMA SENTINEL LYMPH NODE 
ANALYSIS (I) 
10.1 Comparison of RT-PCR and immunohistochemical analyses of sentinel 
lymph nodes (I) 
 Based on the microarray analysis results of micrometastatic SLNs and normal lymph nodes, 
we selected MLANA, TYR, MIA, ERBB3, and PRAME to be tested as markers for detection 
of melanoma micrometastases. To evaluate the diagnostic and prognostic value of MLANA- 
and TYR-RT-PCR compared to standard histopathology and immunohistochemical analysis 
of MLANA and TYR, we analyzed a total of 516 SLNs from 160 patients by these methods. 
A double-marker (MLANA/TYR) IHC analysis identified metastatic disease in 16% (85 of 
516) of the SLNs and 34% (54 of 160) of the patients. MLANA/TYR-RT-PCR assays, in 
turn, suggested a higher rate of micrometastasis, giving a positive result for 25% (128 of 516) 
of the SLNs and 49% (78 of 160) of the patients (I: Supplementary Tables 5 and 6). During a 
median follow-up of 43 months, disease recurred in 34 patients, of which 19 were positive by 
IHC and 26 by RT-PCR (I: Supplementary Table 6). Disease recurrence was associated more 
strongly with a positive RT-PCR result (odds ratio, OR=4.6, p=0.000395), especially at the 
cut-off level of primary PCR (OR=6.3, p=1.27e-05), than with a positive IHC result (OR=3.3, 
p=0.00374). Also poor outcome was more strongly associated with a positive result in RT-
PCR than in IHC (OR=3.5, p=0.0123 for RT-PCR; OR=4.6, p=0.0015 at the cut-off level of 
primary PCR; OR=3.0, p=0.0171 for IHC) (unpublished data). Both primary-PCR- and IHC-
positive patients showed significantly shorter disease-free and disease-specific survival than 
patients with a respective negative result (Figure 9). Combined these results suggest that RT-
PCR may detect clinically significant metastases that are missed by histopathological and 
immunohistochemical examinations. These findings support the implementation of 
quantifiable RT-PCR assays into clinical use to confirm and complement the IHC analysis of 
melanoma-draining SLNs. After our study, the clinical significance of submicroscopic 
metastases and the prognostic value of RT-PCR analyses have remained controversial. An 
earlier large multi-center study (Scoggins et al., 2006) and one smaller more recent study 
(Hilari et al., 2009) were unable to find RT-PCR to provide any additional prognostic 
information in the analysis of SLNs beyond that obtained by standard histopathological 
evaluation. However, in concordance with our results, in a study with a ten-year follow-up, a 
multimarker qRT-PCR assay was found to have prognostic significance in the analysis of 
paraffin-embedded (minimizing sampling error) histopathology-negative SLNs (Nicholl et 
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al., 2011). Also, a single-marker RT-PCR assay has been found to disclose clinically 
significant histopathology-negative metastases (Riber-Hansen et al., 2008).  
 
Figure 9. Kaplan-Meier survival curves for SLN patients. Disease-free (A and B) and disease-specific 
(C and D) survival among patients divided in to groups according to their SLN status determined by 
MLANA/TYR-RT-PCR (A and C) and IHC (B and D) analysis. 
 
We also analyzed a subset of the SLNs by the other candidate markers MIA, ERBB3, and 
PRAME to see if a multiple-marker RT-PCR assay would improve the detection rate.  
Unfortunately, the sensitivity of these markers did not reach that of MLANA- and TYR-RT-
PCR or IHC, with MIA detecting 47% (26 of 55), PRAME 27% (13 of 49), and ERBB3 26% 
(15 of 58) of the SLNs positive by MLANA- and TYR-RT-PCR. As MIA and ERBB3 are 
also expressed by benign nevus cells, they will unlikely provide any additional information to 
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TYR and MLANA in the assessment of melanoma SLNs. However, PRAME, as a 
melanoma-specific marker, may be informative about the malignancy of the cells in the SLN 
when giving a positive result. 
10.2 SPP1 as a melanoma marker (I) 
SPP1 is a multifunctional protein in melanoma progression (Kumar et al., 2013; Yin et al., 
2014; Zhou et al., 2005). As we found SPP1 to be over-expressed both in melanoma lymph 
node metastases compared to normal lymph nodes and in primary melanomas compared to 
benign nevi, we decided to test if SPP1 could be used in IHC as a diagnostic melanoma 
marker. In a pilot study, SPP1 showed positive immunostaining in 13 of the 14 lymph node 
metastases (Figure 10; I: Figure 3). Normal lymph nodes (n=3) showed only weak staining in 
germinal center cells and macrophages (Figure 10). Also benign nevi (n=12) were mostly 
negative for SPP1, with only two showing faint staining (I: Figure 3). In turn, SPP1 was 
found to be expressed in 20 of the 25 primary melanomas, with stronger staining seen in 
patients with metastases, in concordance with our microarray results, where metastatic 
primary melanomas showed 12.6-fold higher expression of SPP1 compared to non-metastatic 
primary melanomas (IV: Supplemental Table S3). After our study, SPP1 expression in 
primary melanomas (large material of 345 samples) was found to be an independent 
prognostic factor, associating with reduced recurrence-free and disease-specific survival, and 
predicting metastasis to SLNs and SLN metastasis burden (Rangel et al., 2008). Our results 
suggest that SPP1 may also serve as a tumor-specific marker in melanoma-draining SLNs, 
the definitive value of which remains to be studied in a larger material. 
 
Figure 10. Immunostaining of SPP1 in a normal lymph node (A) and a melanoma SLN metastasis 
(B). Original magnification 200x (A), 100x (B). 
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CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
The heterogeneity, aggressiveness, and refractoriness to current treatments make 
disseminated melanomas very difficult to cure. The development of whole-genome gene 
expression analysis techniques has allowed the identification of common gene expression 
patterns in tumors, aiding in unraveling the molecular mechanisms behind tumor progression 
and metastasis, and providing novel potential prognostic markers and therapeutic targets. 
In this thesis work, we have identified several genes associated with melanoma development 
and progression and characterized the function of some genes in more detail. The fact that 
many of the identified genes are expressed both by tumor and stromal cells emphasize the 
importance of the tumor microenvironment in the progression and metastasis of melanomas. 
Especially the interplay and reciprocal activation between melanoma cells and fibroblasts 
appears to play an important role in both melanoma cell invasion and in the outgrowth of 
melanoma metastases. Our in vitro invasion analyses suggest that melanoma cells serve as the 
initiators of this interaction by first recruiting and activating fibroblasts, which in turn 
reciprocally activate melanoma cells, leading to increased invasive growth of both cell types. 
The results of our study and previous studies suggest that one of the important mediators of 
this melanoma cell-fibroblast communication, secreted by both cell types, is TGFβ, which 
regulates both the behavior of the cells and the composition of the tumor microenvironment. 
In clinical human melanoma lymph node metastases, TGFβ/Smad2 signaling pathway was 
activated both in the melanoma cells at the tumor edge and in the surrounding fibroblasts, and 
the activation was associated with an up-regulation of the TGFβ-regulated genes encoding 
ECM proteins POSTN, FN1, COL-I, and VCAN. Interestingly, we found these proteins to 
form around melanoma cell nests, especially at the tumor-stroma interface, elaborate fibrillar 
channel-like networks, which, suggested by our functional analyses, support tumor and 
stromal cell growth, and provide the cells a scaffold to attach and a pathway to efficiently 
migrate along. Our in vitro results suggest that the tumor cells harness fibroblasts to aid in 
modifying and invading the surrounding stroma, and to actually lead the way for melanoma 
cells. We found this co-invasive process to be dependent on TGFβ signaling and the activity 
of cathepsins B and L1. It seems that melanoma cells and fibroblasts together first degrade 
the existing ECM to make way for invasion, and then de novo synthesize specific ECM 
molecules and generate a new microenvironment consisting of pro-migratory tubules which 
also aid the migration and invasion of following cells. Importantly, these fibrillar protein 
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networks were also found in melanoma metastases from liver and lung as well as in invasive 
primary melanoma tumors, indicating that melanoma cells modify their microenvironment 
similarly in different local environments. In addition, also breast cancer metastases were 
found to form these structures, suggesting that this is a common phenomenon in tumor 
progression, making TGFβ and especially the TGFβ-regulated FN1 and POSTN rational and 
attractive targets for treating disseminated melanomas and breast cancers as well as 
potentially other cancer. As cathepsins B and L1 were up-regulated (in addition to melanoma 
invasion) in the outgrowth of melanoma lymph node metastases, a combinatorial therapeutic 
approach targeting additionally the activity of these proteases may provide an even more 
effective way to treat disseminated disease and reduce the development of resistance. 
Cathepsin B and L inhibitors are still in pre-clinical testing (Elie et al., 2010; Gondi and Rao, 
2013), but effective anti-TGFβ strategies have already been developed and tested in pre-
clinical and clinical trials with promising results calling for further research and drug design 
(Katz et al., 2013). 
CTHRC1, a gene we found to be up-regulated in the development and progression of primary 
melanomas as well as in the growth melanoma metastases, also provides an attractive target 
to treat metastatic and disseminated melanomas, interfering with melanoma cell migration 
and invasion, and potentially angiogenesis. Further, a targeted inhibition of NFATC2, an 
upstream regulator of CTHRC1, in the tumor cells and the tumor endothelium is an 
interesting therapeutic strategy against metastatic tumors. In addition, FN1, the expression of 
which we found to correlate with that of CTHRC1 in primary melanomas and melanoma cell 
lines, as well as POSTN, were found to be specifically over-expressed in newly-formed 
tumor blood vessels, and provide, in the light of also previous results, interesting potential 
targets for anti-angiogenic therapies. The specific function of these proteins in tumor 
angiogenesis is an interesting subject of future studies. Importantly, our results additionally 
suggest that high expression of CTHRC1 and FN1 as well as CTSB in primary melanomas 
may serve as prognostic factors predicting poor survival. 
In another part of this study, we identified the best diagnostic markers for melanoma SLN 
metastasis and compared the significance of RT-PCR and IHC analyses in the detection of 
micrometastatic disease. There has been a lot of debate of the usefulness of RT-PCR in the 
analysis of melanoma SLNs and the clinical significance of submicroscopic metastases. In 
our analyses, RT-PCR was able to disclose clinically significant metastases better than 
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immunohistochemical analyses suggesting that quantifiable RT-PCR assays should be 
implemented in to clinical use to confirm and complement IHC analyses. The definitive value 
of the identified tumor-specific markers, PRAME and SPP1, in the analysis of melanoma-
draining SLNs remains a target of future studies. Both of these genes serve also as potential 
therapeutic targets. One approach to target PRAME could be the use of PRAME-specific 
cytotoxic T lymphocytes tested already for the immunotherapy of PRAME-positive 
hematologic malignancies (Quintarelli et al., 2011). In turn, recently published results by our 
group (Yin et al., 2014) suggest that targeting both SPP1 and its down-stream target CD9 
might provide an effective approach to treat metastatic melanomas. 
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